School of Medicine Homepage
Emory University Shield
  • About
    • Our Vision
    • Academic Departments
    • Our Leadership
    • Health Care Partnerships
    • Diversity, Equity, & Inclusion
    • Location
    • Supporting Our People
    • Our Faculty
    • History
    • News
    • Events
    • Contact Us
  • Education
    • Degree and Certificate Programs
    • Academic Departments
    • Residents & Fellows
    • Postdoctoral Training
    • Continuing Medical Education
    • Admissions
    • Cost and Financial Aid
    • Student Resources
  • Research
    • Research Innovation
    • Conducting Research
    • Core Facilities
    • Research Centers
    • Research Training
    • Academic Departments
    • Find a Researcher
    • Research News
  • Clinical Experience
    • Where We Work
    • Caring for a Diverse Population
    • Faculty Clinical Experience
    • Advanced Patient Care
    • Academic Departments
    • Community Learning
  • Giving
  • Directory

Directory section navigation

  • Faculty Profiles

Emory University School of Medicine

  • About
    • Sub link
      Our Vision
    • Sub link
      Academic Departments
    • Sub link
      Our Leadership
    • Sub link
      Health Care Partnerships
    • Sub link
      Diversity, Equity, & Inclusion
    • Sub link
      Location
    • Sub link
      Supporting Our People
    • Sub link
      Our Faculty
    • Sub link
      History
    • Sub link
      News
    • Sub link
      Events
    • Sub link
      Contact Us
  • Education
    • Sub link
      Degree and Certificate Programs
    • Sub link
      Academic Departments
    • Sub link
      Residents & Fellows
    • Sub link
      Postdoctoral Training
    • Sub link
      Continuing Medical Education
    • Sub link
      Admissions
    • Sub link
      Cost and Financial Aid
    • Sub link
      Student Resources
  • Research
    • Sub link
      Research Innovation
    • Sub link
      Conducting Research
    • Sub link
      Core Facilities
    • Sub link
      Research Centers
    • Sub link
      Research Training
    • Sub link
      Academic Departments
    • Sub link
      Find a Researcher
    • Sub link
      Research News
  • Clinical Experience
    • Sub link
      Where We Work
    • Sub link
      Caring for a Diverse Population
    • Sub link
      Faculty Clinical Experience
    • Sub link
      Advanced Patient Care
    • Sub link
      Academic Departments
    • Sub link
      Community Learning
  • Giving
  • Directory
  • Home School of Medicine Home
  • Directory

Profile

Martin Sanda MD

  • Department of Urology
    Professor
  • (404) 778-6874
Head shot of Martin Sanda

Overview

Dr. Sanda is an internationally recognized prostate cancer surgeon and scientist. In 2013, he was appointed chair of the Department of Urology at Emory University School of Medicine, urology service chief for Emory Healthcare, and director of the Prostate Cancer Center of Emory's Winship Cancer Institute.

Dr. Sanda came to Emory from Harvard Medical School and Beth Israel Deaconess Medical Center, where he served as director of the Prostate Cancer Center. He was also the co-leader of the Prostate Cancer Program at the Dana Farber Cancer Center.

After receiving his MD degree at Columbia University, Dr. Sanda did his general surgery residency at the Medical College of Virginia and completed his surgical oncology fellowship at the National Cancer Institute. His urology residency was completed at Johns Hopkins Hospital.

Dr. Sanda's clinical expertise focuses on prostate cancer multidisciplinary care, active surveillance, and robotic prostatectomy, while his academic specialties include prostate cancer immunology, biomarker, and patient-reported outcomes research. He has held continuous NIH funding for over 20 years as Principal Investigator of studies evaluating prostate cancer detection, immunotherapy, and quality of life.

He is the principal investigator of three multi-center consortium studies funded by the National Cancer Institute and the Prostate Cancer Foundation: the first is seeking to develop urine tests for detecting prostate cancer, the second is developing benchmarks for improving quality of life among cancer survivors, and the third is working to develop innovative prostate cancer vaccines. The findings of these studies thus far have been published in leading medical journals including the Journal of the American Medical Association and The New England Journal of Medicine.

Dr. Sanda has served as chair of the Prostate and Genito-Urinary Collaborative Group of the National Cancer Institute's Early Detection Research Network, chair of the AUA-SUO-ASTRO Committee on Localized Prostate Cancer Treatment Guidelines, and as a member of numerous federal funding review panels.

Academic Appointment

  • Professor of Urology, Emory University

Education

Degrees

  • MD from Columbia University College of Physicians and Surgeons
  • BA from Yale University

Research

Focus

  • I established a prostate cancer immunology laboratory as PI in 1996 and have held continuous NIH funding since then. The scope of my prostate cancer research expanded to evaluating prostate cancer antigens as markers for early detection and to investigating patient-reported outcomes among prostate cancer survivors.

Publications

  • Utilization, health care expenditures, and patient costs of definitive treatment modalities for localized prostate cancer in the United States.
    Cancer Volume: 131 Page(s): e35795
    03/15/2025 Authors: Sebastian NT; Patil D; Patel PR; Jani AB; Hershatter BW; Dhere VR; Godette KD; Lorentz CA; Weiss AD; Joshi SS
  • A simplified MyProstateScore2.0 for high-grade prostate cancer.
    Cancer Biomark Volume: 42 Page(s): 18758592241308755
    01/01/2025 Authors: Tang TM; Zhang Y; Kenney AM; Xie C; Xiao L; Siddiqui J; Srivastava S; Sanda MG; Wei JT; Feng Z
  • Differentiation fate of a stem-like CD4 T cell controls immunity to cancer.
    Nature Volume: 636 Page(s): 224 - 232
    12/01/2024 Authors: Cardenas MA; Prokhnevska N; Sobierajska E; Gregorova P; Medina CB; Valanparambil RM; Greenwald R; DelBalzo L; Bilen MA; Joshi SS
  • Author Correction: Differentiation fate of a stem-like CD4 T cell controls immunity to cancer.
    Nature Volume: 635 Page(s): E9
    11/01/2024 Authors: Cardenas MA; Prokhnevska N; Sobierajska E; Gregorova P; Medina CB; Valanparambil RM; Greenwald R; DelBalzo L; Bilen MA; Joshi SS
  • The diagnostic challenges of differentiating metastatic extramammary Paget disease and prostatic adenocarcinoma: A case report and review of the literature.
    Urol Case Rep Volume: 57 Page(s): 102875
    11/01/2024 Authors: Palmateer G; Nicaise EH; Gandhi J; Goodstein T; Sheng M; Ogan K; Kucuk O; Yushak M; Sanda MG; Delman KA
  • Upgrading of Grade Group 1 Prostate Cancer at Prostatectomy: Germline Risk Factors in a Prospective Cohort.
    Cancer Epidemiol Biomarkers Prev Volume: 33 Page(s): 1500 - 1511
    11/01/2024 Authors: Liss MA; Zeltser N; Zheng Y; Lopez C; Liu M; Patel Y; Yamaguchi TN; Eng SE; Tian M; Semmes OJ
  • Postprostatectomy Radiotherapy Timing and Long-Term Health-Related Quality of Life.
    JAMA Netw Open Volume: 7 Page(s): e2440747
    10/01/2024 Authors: Patel SA; Patil D; Smith J; Saigal CS; Litwin MS; Hu JC; Cooperberg MR; Carroll PR; Klein EA; Kibel AS
  • Development and Validation of an 18-Gene Urine Test for High-Grade Prostate Cancer.
    JAMA Oncol Volume: 10 Page(s): 726 - 736
    06/01/2024 Authors: Tosoian JJ; Zhang Y; Xiao L; Xie C; Samora NL; Niknafs YS; Chopra Z; Siddiqui J; Zheng H; Herron G
  • Integrated Genomic Analysis of Primary Prostate Tumor Foci and Corresponding Lymph Node Metastases Identifies Mutations and Pathways Associated with Metastasis.
    Cancers (Basel) Volume: 15
    11/30/2023 Authors: Moreno CS; Winham CL; Alemozaffar M; Klein ER; Lawal IO; Abiodun-Ojo OA; Patil D; Barwick BG; Huang Y; Schuster DM
  • Effect of Brachytherapy With External Beam Radiation Therapy Versus Brachytherapy Alone for Intermediate-Risk Prostate Cancer: NRG Oncology RTOG 0232 Randomized Clinical Trial.
    J Clin Oncol Volume: 41 Page(s): 4035 - 4044
    08/20/2023 Authors: Michalski JM; Winter KA; Prestidge BR; Sanda MG; Amin M; Bice WS; Gay HA; Ibbott GS; Crook JM; Catton CN
  • Covariate-specific evaluation of continuous biomarker.
    Stat Med Volume: 42 Page(s): 953 - 969
    03/30/2023 Authors: Li Z; Huang Y; Patil D; Rubin M; Sanda MG
  • Covariate adjustment in continuous biomarker assessment.
    Biometrics Volume: 79 Page(s): 39 - 48
    03/01/2023 Authors: Li Z; Huang Y; Patil D; Sanda MG
  • CD8+ Tcell activation in cancer comprises an initial activation phase in lymph nodes followed by effector differentiation within the tumor.
    Immunity Volume: 56 Page(s): 107 - 124.e5
    01/10/2023 Authors: Prokhnevska N; Cardenas MA; Valanparambil RM; Sobierajska E; Barwick BG; Jansen C; Reyes Moon A; Gregorova P; delBalzo L; Greenwald R
  • Interval estimation for operating characteristic of continuous biomarkers with controlled sensitivity or specificity.
    Stat Sin Volume: 33 Page(s): 193 - 214
    01/01/2023 Authors: Huang Y; Parakati I; Patil DH; Sanda MG
  • Invariant NKT cell-augmented GM-CSF-secreting tumor vaccine is effective in advanced prostate cancer model.
    Cancer Immunol Immunother Volume: 71 Page(s): 2943 - 2955
    12/01/2022 Authors: Varghese B; Lynch L; Vriend LE; Draganov D; Clark JM; Kissick HT; Varghese S; Sanda MG; Dranoff G; Arredouani MS
  • Impact of Prostate Health Index Results for Prediction of Biopsy Grade Reclassification During Active Surveillance.
    J Urol Volume: 208 Page(s): 1037 - 1045
    11/01/2022 Authors: Filson CP; Zhu K; Huang Y; Zheng Y; Newcomb LF; Williams S; Brooks JD; Carroll PR; Dash A; Ellis WJ
  • Cost-effectiveness analysis of primary treatments for localised prostate cancer: A population-based Markov analysis using real-world evidence.
    Eur J Cancer Care (Engl) Volume: 31 Page(s): e13740
    11/01/2022 Authors: Weng X; Zhong L; Xiang P; Li Y; Paciorek A; Dong L; Broering J; Carroll PR; Sanda M; Wilson L
  • LINEAR BIOMARKER COMBINATION FOR CONSTRAINED CLASSIFICATION.
    Ann Stat Volume: 50 Page(s): 2793 - 2815
    10/01/2022 Authors: Huang Y; Sanda MG
  • Patient reported outcomes for quality of life (QOL) by Expanded Prostate Cancer Index (EPIC) on average 15 years post treatment.
    Clin Transl Radiat Oncol Volume: 36 Page(s): 56 - 62
    09/01/2022 Authors: Seymour ZA; Daignault-Newton S; McLaughlin PW; Sandler H; Jackson W; Johnson SB; Miller D; Wei J; Sanda M; Hamstra DA
  • High throughput, label-free isolation of circulating tumor cell clusters in meshed microwells.
    Nat Commun Volume: 13 Page(s): 3385
    06/13/2022 Authors: Boya M; Ozkaya-Ahmadov T; Swain BE; Chu C-H; Asmare N; Civelekoglu O; Liu R; Lee D; Tobia S; Biliya S
  • Association of race with receipt of definitive therapy for high risk prostate cancer in older men.
    J Geriatr Oncol Volume: 13 Page(s): 200 - 206
    03/01/2022 Authors: Patel SA; Liu Y; Mahal BA; Jani AB; Sanda MG; Royce TJ; Fischer-Valuck BW
  • Treatment Patterns and Overall Survival Outcomes Among Patients Aged 80 yr or Older with High-risk Prostate Cancer.
    Eur Urol Open Sci Volume: 37 Page(s): 80 - 89
    03/01/2022 Authors: Fischer-Valuck BW; Baumann BC; Brown SA; Filson CP; Weiss A; Mueller R; Liu Y; Brenneman RJ; Sanda M; Michalski JM
  • Collision tumors revealed by prospectively assessing subtype-defining molecular alterations in 904 individual prostate cancer foci.
    JCI Insight Volume: 7
    02/22/2022 Authors: Fontugne J; Cai PY; Alnajar H; Bhinder B; Park K; Ye H; Beg S; Sailer V; Siddiqui J; Blattner-Johnson M
  • Cancer-specific outcomes for prostate cancer patients who had prebiopsy prostate MRI.
    Urol Oncol Volume: 40 Page(s): 58.e9 - 58.e15
    02/01/2022 Authors: Li J; Patil D; Sanda MG; Filson CP
  • Genetic Factors Associated with Prostate Cancer Conversion from Active Surveillance to Treatment.
    HGG Adv Volume: 3
    01/13/2022 Authors: Jiang Y; Meyers TJ; Emeka AA; Cooley LF; Cooper PR; Lancki N; Helenowski I; Kachuri L; Lin DW; Stanford JL
  • Prospective Multicenter Comparison of Open and Robotic Radical Prostatectomy: The PROST-QA/RP2 Consortium.
    J Urol Volume: 207 Page(s): 127 - 136
    01/01/2022 Authors: Chang P; Wagner AA; Regan MM; Smith JA; Saigal CS; Litwin MS; Hu JC; Cooperberg MR; Carroll PR; Klein EA
  • CD8 T CELL ACTIVATION IN CANCER IS COMPRISED OF TWO DISTINCT PHASES
    Volume: 9 Page(s): A686 - A686
    11/01/2021 Authors: Prokhnevska N; Cardenas M; Valanparambil R; Sobierajska E; Jansen C; Master V; Sanda M; Kissick H
  • UTILITY OF DIGITAL RECTAL EXAM FOR PROSTATE CANCER SCREENING AMONG MEN WITH LOW PSA VALUES
    Volume: 206 Page(s): E471 - E471
    09/01/2021 Authors: Brownfield C; Harik L; Kowalczyk K; Patil D; Sanda M; Osunkoya A; Filson C
  • PROSTATE HEALTH INDEX IN PREDICTING GRADE RECLASSIFICATION ON BIOPSY FOR MEN ON ACTIVE SURVEILLANCE
    Volume: 206 Page(s): E1095 - E1096
    09/01/2021 Authors: Filson C; Sokoll L; Zheng Y; Huang Y; Newcomb L; Zhu K; Williams S; Sanda M; Chan D; Lin D
  • Disparities in magnetic resonance imaging of the prostate for traditionally underserved patients with prostate cancer.
    Cancer Volume: 127 Page(s): 2974 - 2979
    08/15/2021 Authors: Quinn TP; Sanda MG; Howard DH; Patil D; Filson CP
  • Decision regret, adverse outcomes, and treatment choice in men with localized prostate cancer: Results from a multi-site randomized trial.
    Urol Oncol Volume: 39 Page(s): 493.e9 - 493.e15
    08/01/2021 Authors: Berry DL; Hong F; Blonquist TM; Halpenny B; Xiong N; Filson CP; Master VA; Sanda MG; Chang P; Chien GW
  • CD8 T cell differentiation in cancer is comprised of two distinct phases
    Volume: 206
    05/01/2021 Authors: Prokhnevska N; Cardenas M; Valanparambil R; Jansen C; Master V; Sanda M; Kissick H
  • A panel of selected serum protein biomarkers for the detection of aggressive prostate cancer.
    Theranostics Volume: 11 Page(s): 6214 - 6224
    01/01/2021 Authors: Song J; Ma S; Sokoll LJ; Eguez RV; Hti N; Zhang H; Mohr P; Dua R; Patil D; May KD
  • Prostate Cancer Biomarker Development: National Cancer Institute's Early Detection Research Network Prostate Cancer Collaborative Group Review.
    Cancer Epidemiol Biomarkers Prev Volume: 29 Page(s): 2454 - 2462
    12/01/2020 Authors: Liss MA; Leach RJ; Sanda MG; Semmes OJ
  • External Validation of Early Quality of Life (QOL) Declines Correlated with Late QOL after Intensity Modulated, Low Dose Rate Brachytherapy, or Stereotactic Radiation for Prostate Cancer within a Prospective Trial
    Volume: 108 Page(s): S69 - S69
    11/01/2020 Authors: Seymour ZA; Hamstra DA; Daignault-Newton S; Thompson A; Sanda MG; Michalski JM; Zietman AL; Kuban DA; Ciezki JP; Kaplan ID
  • [18F]Fluciclovine Positron Emission Tomography/Computerized Tomography for Preoperative Staging in Patients with Intermediate to High Risk Primary Prostate Cancer.
    J Urol Volume: 204 Page(s): 734 - 740
    10/01/2020 Authors: Alemozaffar M; Akintayo AA; Abiodun-Ojo OA; Patil D; Saeed F; Huang Y; Osunkoya AO; Goodman MM; Sanda M; Schuster DM
  • In-Bore MRI-guided Prostate Biopsies in Patients with Prior Positive Transrectal US-guided Biopsy Results: Pathologic Outcomes and Predictors of Missed Cancers.
    Radiol Imaging Cancer Volume: 2 Page(s): e190078
    09/25/2020 Authors: Elfatairy KK; Filson CP; Sanda MG; Osunkoya AO; Nour SG
  • Cancer and Leukemia Group B 90203 (Alliance): Radical Prostatectomy With or Without Neoadjuvant Chemohormonal Therapy in Localized, High-Risk Prostate Cancer.
    J Clin Oncol Volume: 38 Page(s): 3042 - 3050
    09/10/2020 Authors: Eastham JA; Heller G; Halabi S; Monk JP; Beltran H; Gleave M; Evans CP; Clinton SK; Szmulewitz RZ; Coleman J
  • Tumor-specific CD8 T cell activation in draining lymph nodes supports the anti-tumor CD8 T cell response
    Volume: 204
    05/01/2020 Authors: Prokhnevska N; Cardenas M; Jansen C; Valanparambil R; Master V; Sanda M; Kissick H
  • [18F]fluciclovine PET/CT versus multiparametric MRI assessment of seminal vesicle invasion and extracapsular extension in patients with primary prostate cancer.
    Volume: 61
    05/01/2020 Authors: Akintayo A; Abiodun-Ojo O; Alemozaffar M; Akin-Akintayo O; Patil D; Huang Y; Osunkoya A; Sanda M; Schuster D
  • PREOPERATIVE F-18-FLUCICLOVINE PET/CT FINDINGS MAY BE PREDICTIVE OF POST-OPERATIVE PROSTATE-SPECIFIC ANTIGEN (PSA) IN PATIENTS WITH HIGH RISK PROSTATE CANCER
    Volume: 203 Page(s): E1026 - E1026
    04/01/2020 Authors: Akintayo A; Abiodun-Ojo O; Alemozaffar M; Akin-Akintayo O; Patil D; Osunkoya A; Sanda M; Schuster D
  • IMPACT OF PREBIOPSY PROSTATE MRI ON BIOPSY RESULTS, INITIAL TREATMENT, AND PROSTATECTOMY OUTCOMES FOR MEDICARE-ELIGIBLE PROSTATE CANCER PATIENTS
    Volume: 203 Page(s): E806 - E806
    04/01/2020 Authors: Li J; Patil D; Sanda M; Howard D; Filson C
  • DISPARITIES IN USE OF PREBIOPSY PROSTATE MAGNETIC RESONANCE IMAGING FOR MEDICARE-ELIGIBLE PROSTATE CANCER PATIENTS
    Volume: 203 Page(s): E817 - E817
    04/01/2020 Authors: Quinn T; Patil D; Sanda M; Howard D; Filson C
  • A prospective study of patient reported urinary incontinence among American, Norwegian and Spanish men 1 year after prostatectomy.
    Asian J Urol Volume: 7 Page(s): 161 - 169
    04/01/2020 Authors: Stors AH; Sanda MG; Garin O; Chang P; Patil D; Crociani C; Suarez JF; Cvancarova M; Loge JH; Foss SD
  • An intra-tumoral niche maintains and differentiates stem-like CD8 T cells.
    Nature Volume: 576 Page(s): 465 - 470
    12/01/2019 Authors: Jansen CS; Prokhnevska N; Master VA; Sanda MG; Carlisle JW; Bilen MA; Cardenas M; Wilkinson S; Lake R; Sowalsky AG
  • How tumor-specific CD8 T cell activation in draining lymph nodes supports the anti-tumor CD8 T cell response
    Volume: 7
    11/06/2019 Authors: Prokhnevska N; Valanparambil R; Jansen C; Master V; Sanda M; Kissick H
  • In-Bore MRI-guided Prostate Biopsies: Retrospective Observational Study of Complementary Nontargeted Sampling of Normal-appearing Areas at Multiparametric MRI.
    Radiol Imaging Cancer Volume: 1 Page(s): e190016
    11/01/2019 Authors: Elfatairy KK; Filson CP; Sanda MG; Osunkoya AO; Nour SG
  • A four-group urine risk classifier for predicting outcomes in patients with prostate cancer.
    BJU Int Volume: 124 Page(s): 609 - 620
    10/01/2019 Authors: Connell SP; Yazbek-Hanna M; McCarthy F; Hurst R; Webb M; Curley H; Walker H; Mills R; Ball RY; Sanda MG
  • Circulating microRNAs in plasma among men with low-grade and high-grade prostate cancer at prostate biopsy.
    Prostate Volume: 79 Page(s): 961 - 968
    06/01/2019 Authors: McDonald AC; Vira M; Walter V; Shen J; Raman JD; Sanda MG; Patil D; Taioli E
  • Rise in Node-Positive Prostate Cancer Incidence in Context of Evolving Use and Extent of Pelvic Lymphadenectomy.
    Clin Genitourin Cancer Volume: 17 Page(s): e494 - e504
    06/01/2019 Authors: Taylor MA; Alemozaffar M; Master VA; Sanda MG; Filson CP
  • [F-18] fluciclovine PET/CT is superior to conventional imaging in preoperative nodal staging in patients with high-risk prostate cancer
    Volume: 60
    05/01/2019 Authors: Akintayo A; Abiodun-Ojo O; Alemozaffar M; Osunkoya A; Sanda M; Schuster D
  • Preoperative staging in high risk prostate cancer patients using F-18] fluctclovine PET/CT
    Volume: 60
    05/01/2019 Authors: Akintayo A; Abiodun-Ojo O; Alemozaffar M; Osunkoya A; Sanda M; Schuster D
  • Expanded Prostate Cancer Index Composite-26 (EPIC-26) Online: Validation of an Internet-Based Instrument for Assessment of Health-Related Quality of Life After Treatment for Localized Prostate Cancer.
    Urology Volume: 127 Page(s): 53 - 60
    05/01/2019 Authors: Einstein DJ; Patil D; Chipman J; Regan MM; Davis K; Crociani CM; Wagner AA; Sanda MG; Chang P
  • EVALUATION OF FLUCICLOVINE (FACBC) PET SCAN FOR STAGING HIGH-RISK PROSTATE CANCER BEFORE PRIMARY TREATMENT
    Volume: 201 Page(s): E396 - E396
    04/01/2019 Authors: Alemozaffar M; Akintayo A; Abiodun-Ojo O; Huang E; Patil D; Giles S; Torlak M; Sanda M; Schuster D
  • Impact of prebiopsy magnetic resonance imaging of the prostate on cancer detection and treatment patterns.
    Urol Oncol Volume: 37 Page(s): 181.e15 - 181.e21
    03/01/2019 Authors: Liu W; Patil D; Howard DH; Moore RH; Wang H; Sanda MG; Filson CP
  • Evaluating Clinical Implementation Approaches for Prostate Cancer Decision Support.
    Urol Pract Volume: 6 Page(s): 93 - 99
    03/01/2019 Authors: Berry DL; Hong F; Halpenny B; Sanda MG; Master VA; Filson CP; Chang P; Chien GW; Underhill M; Fox E
  • Genitourinary Prosthetic Use among Prostate Cancer Survivors Treated with Radical Prostatectomy.
    Urol Pract Volume: 6 Page(s): 123 - 128
    03/01/2019 Authors: Aliperti LA; Patil D; Filson CP; Hartsell LM; Carney KJ; Sanda MG; Mehta A
  • Safety of high dose rate prostate brachytherapy in patients with high baseline international prostate symptom scores.
    Volume: 37
    03/01/2019 Authors: Morgan T; Rossi PJ; Cutrell P; Zhang C; Press RH; Rahnema S; Sanda MG; Pattaras J; Cimmino CB; Jani AB
  • Elevated Serum Cytokines and Trichomonas vaginalis Serology at Diagnosis Are Not Associated With Higher Gleason Grade or Lethal Prostate Cancer.
    Clin Genitourin Cancer Volume: 17 Page(s): 32 - 37
    02/01/2019 Authors: Vicier C; Werner L; Chipman J; Harshman LC; Patil DH; Fichorova RN; Rider JR; Sanda MG; Mucci LA; Sweeney CJ
  • Assigning value to preparation for prostate cancer decision making: a willingness to pay analysis.
    BMC Med Inform Decis Mak Volume: 19 Page(s): 6
    01/09/2019 Authors: Wilson LS; Blonquist TM; Hong F; Halpenny B; Wolpin S; Chang P; Filson CP; Master VA; Sanda MG; Chien GW
  • Incorporation of Urinary Prostate Cancer Antigen 3 and TMPRSS2:ERG into Prostate Cancer Prevention Trial Risk Calculator.
    Eur Urol Focus Volume: 5 Page(s): 54 - 61
    01/01/2019 Authors: Ankerst DP; Goros M; Tomlins SA; Patil D; Feng Z; Wei JT; Sanda MG; Gelfond J; Thompson IM; Leach RJ
  • epiCaPture: A Urine DNA Methylation Test for Early Detection of Aggressive Prostate Cancer.
    JCO Precis Oncol Volume: 2019
    01/01/2019 Authors: O'Reilly E; Tuzova AV; Walsh AL; Russell NM; O'Brien O; Kelly S; Dhomhnallain ON; DeBarra L; Dale CM; Brugman R
  • High-dose-rate prostate brachytherapy appears safe in patients with high baseline International Prostate Symptom Scores.
    Brachytherapy Volume: 18 Page(s): 793 - 799
    01/01/2019 Authors: Morgan TM; Rossi PJ; Cutrell PK; Zhang C; Press RH; Rahnema S; Sanda M; Pattaras J; Cimmino C; Hershatter B
  • Patient-reported health-related quality of life outcomes after HDR brachytherapy between small (<60cc) and large (60cc) prostate glands.
    Brachytherapy Volume: 18 Page(s): 13 - 21
    01/01/2019 Authors: Press RH; Morgan TM; Cutrell PK; Zhang C; Chen Z; Rahnema S; Sanda M; Pattaras J; Patel P; Jani AB
  • Brachytherapy for localized prostate cancer in the modern era: a comparison of patient-reported quality of life outcomes among different techniques.
    J Contemp Brachytherapy Volume: 10 Page(s): 495 - 502
    12/01/2018 Authors: Morgan TM; Press RH; Cutrell PK; Zhang C; Chen Z; Rahnema S; Sanda M; Pattaras J; Patel PR; Jani AB
  • Adoption of Prebiopsy Magnetic Resonance Imaging for Men Undergoing Prostate Biopsy in the United States.
    Urology Volume: 117 Page(s): 57 - 63
    07/01/2018 Authors: Liu W; Patil D; Howard DH; Moore RH; Wang H; Sanda MG; Filson CP
  • Hypofractionated external beam radiation therapy in combination with HDR boost for localized prostate cancer: patient reported quality of life outcomes.
    J Contemp Brachytherapy Volume: 10 Page(s): 211 - 217
    06/01/2018 Authors: Morgan TM; Press RH; Cutrell PK; Zhang C; Chen Z; Rahnema S; Jhaveri J; Sanda M; Pattaras J; Patel P
  • Patient-reported outcomes after treatment for clinically localized prostate cancer: A systematic review and meta-analysis.
    Cancer Treat Rev Volume: 66 Page(s): 23 - 44
    05/01/2018 Authors: vila M; Patel L; Lpez S; Corts-Sanabria L; Garin O; Pont ; Ferrer F; Boladeras A; Zamora V; Foss S
  • Circulating microRNAs in plasma as potential biomarkers for the early detection of prostate cancer.
    Prostate Volume: 78 Page(s): 411 - 418
    05/01/2018 Authors: McDonald AC; Vira M; Shen J; Sanda M; Raman JD; Liao J; Patil D; Taioli E
  • PROSTATE BIOPSY COSTS FOR PRIVATELY-INSURED MEN: IMPACT OF MAGNETIC RESONANCE IMAGE-GUIDANCE AND USE OF ANESTHESIA SERVICES
    Volume: 199 Page(s): E1023 - E1023
    04/01/2018 Authors: Leung A; Liu W; Patil D; Henry M; Howard D; Wang H; Moore R; Sanda M; Filson C
  • Clinically Localized Prostate Cancer: AUA/ASTRO/SUO Guideline. Part II: Recommended Approaches and Details of Specific Care Options.
    J Urol Volume: 199 Page(s): 990 - 997
    04/01/2018 Authors: Sanda MG; Cadeddu JA; Kirkby E; Chen RC; Crispino T; Fontanarosa J; Freedland SJ; Greene K; Klotz LH; Makarov DV
  • In-bore MRI-guided biopsy: can it optimize the need for periodic biopsies in prostate cancer patients undergoing active surveillance? A pilot test-retest reliability study.
    Br J Radiol Volume: 91 Page(s): 20170603
    04/01/2018 Authors: Elfatairy KK; Filson CP; Sanda MG; Osunkoya AO; Geller RL; Nour SG
  • Predictors of Patient and Partner Satisfaction Following Radical Prostatectomy.
    Sex Med Rev Volume: 6 Page(s): 295 - 301
    04/01/2018 Authors: Guercio C; Mehta A
  • DETECTION OF PROSTATE CANCER-ASSOCIATED TRANSCRIPTS IN URINARY EXTRACELLULAR VESICLES
    Volume: 199 Page(s): E450 - E451
    04/01/2018 Authors: Pellegrini K; Patil D; Douglas K; Anastasiades E; Larsen K; Kim F; Catic A; Torlak M; Huang E; Moreno C
  • Clinically Localized Prostate Cancer: AUA/ASTRO/SUO Guideline. Part I: Risk Stratification, Shared Decision Making, and Care Options.
    J Urol Volume: 199 Page(s): 683 - 690
    03/01/2018 Authors: Sanda MG; Cadeddu JA; Kirkby E; Chen RC; Crispino T; Fontanarosa J; Freedland SJ; Greene K; Klotz LH; Makarov DV
  • Hypofractionated external beam radiation therapy in combination with HDR boost for localized prostate cancer: Quality of life outcomes.
    Volume: 36
    02/20/2018 Authors: Morgan T; Press RH; Cutrell P; Zhang C; Chen Z; Rahnema S; Sanda MG; Pattaras J; Patel PR; Jani AB
  • NATIONWIDE UTILIZATION OF RECONSTRUCTIVE UROLOGICAL PROCEDURES TO MITIGATE SEXUAL AND URINARY COMPLICATIONS FOLLOWING RADICAL PROSTATECTOMY
    Volume: 15 Page(s): S91 - S91
    02/01/2018 Authors: Aliperti L; Patil D; Filson C; Carney K; Sanda M; Mehta A
  • Predicting erectile function following external beam radiation therapy or brachytherapy for prostate cancer using EPIC-CP.
    Pract Radiat Oncol Volume: 8 Page(s): 445 - 451
    01/01/2018 Authors: Mihalcik SA; Chipman JJ; Sanda MG; Regan MM; Kaplan ID; Wagner AA; Crociani CM; Chang P; PROST-QA Consortium
  • Decision Support with the Personal Patient Profile-Prostate: A Multicenter Randomized Trial.
    J Urol Volume: 199 Page(s): 89 - 97
    01/01/2018 Authors: Berry DL; Hong F; Blonquist TM; Halpenny B; Filson CP; Master VA; Sanda MG; Chang P; Chien GW; Jones RA
  • Patients with Intermediate Risk Prostate Cancer May be Good Candidates for Active Surveillance: Pro.
    J Urol Volume: 198 Page(s): 997 - 999
    11/01/2017 Authors: Sanda MG
  • Early Adoption of MRI-Guided Prostate Biopsies Rose Rapidly among Men with Private Health Insurance
    Volume: 225 Page(s): S114 - S115
    10/01/2017 Authors: Liu W; Patil D; Howard DH; Moore RH; Wang H; Sanda MG; Filson CP
  • Association Between Combined TMPRSS2:ERG and PCA3 RNA Urinary Testing and Detection of Aggressive Prostate Cancer.
    JAMA Oncol Volume: 3 Page(s): 1085 - 1093
    08/01/2017 Authors: Sanda MG; Feng Z; Howard DH; Tomlins SA; Sokoll LJ; Chan DW; Regan MM; Groskopf J; Chipman J; Patil DH
  • Gleason Score 7 Prostate Cancers Emerge through Branched Evolution of Clonal Gleason Pattern 3 and 4.
    Clin Cancer Res Volume: 23 Page(s): 3823 - 3833
    07/15/2017 Authors: Sowalsky AG; Kissick HT; Gerrin SJ; Schaefer RJ; Xia Z; Russo JW; Arredouani MS; Bubley GJ; Sanda MG; Li W
  • Racial Variation in the Utility of Urinary Biomarkers PCA3 and T2ERG in a Large Multicenter Study.
    J Urol Volume: 198 Page(s): 42 - 49
    07/01/2017 Authors: O'Malley PG; Nguyen DP; Al Hussein Al Awamlh B; Wu G; Thompson IM; Sanda M; Rubin M; Wei JT; Lee R; Christos P
  • Prostate Health Index improves multivariable risk prediction of aggressive prostate cancer.
    BJU Int Volume: 120 Page(s): 61 - 68
    07/01/2017 Authors: Loeb S; Shin SS; Broyles DL; Wei JT; Sanda M; Klee G; Partin AW; Sokoll L; Chan DW; Bangma CH
  • Detection of prostate cancer-specific transcripts in extracellular vesicles isolated from post-DRE urine.
    Prostate Volume: 77 Page(s): 990 - 999
    06/01/2017 Authors: Pellegrini KL; Patil D; Douglas KJS; Lee G; Wehrmeyer K; Torlak M; Clark J; Cooper CS; Moreno CS; Sanda MG
  • Evaluation of a 24-gene signature for prognosis of metastatic events and prostate cancer-specific mortality.
    BJU Int Volume: 119 Page(s): 961 - 967
    06/01/2017 Authors: Pellegrini KL; Sanda MG; Patil D; Long Q; Santiago-Jimnez M; Takhar M; Erho N; Yousefi K; Davicioni E; Klein EA
  • External Beam Radiation Therapy or Brachytherapy With or Without Short-course Neoadjuvant Androgen Deprivation Therapy: Results of a Multicenter, Prospective Study of Quality of Life.
    Int J Radiat Oncol Biol Phys Volume: 98 Page(s): 304 - 317
    06/01/2017 Authors: Gay HA; Sanda MG; Liu J; Wu N; Hamstra DA; Wei JT; Dunn RL; Klein EA; Sandler HM; Saigal CS
  • Neoadjuvant Enzalutamide Prior to Prostatectomy.
    Clin Cancer Res Volume: 23 Page(s): 2169 - 2176
    05/01/2017 Authors: Montgomery B; Tretiakova MS; Joshua AM; Gleave ME; Fleshner N; Bubley GJ; Mostaghel EA; Chi KN; Lin DW; Sanda M
  • PERSONALIZED DECISION SUPPORT FOR LOCALIZED PROSTATE CANCER: RESULTS OF A MULTI-SITE RANDOMIZED TRIAL
    Volume: 197 Page(s): E122 - E122
    04/01/2017 Authors: Berry D; Hong F; Blonquist T; Halpenny B; Sanda M; Master V; Filson C; Rossi P; Chang P; Chien G
  • POPULATION-LEVEL CANCER DETECTION AND PATTERNS OF CARE FOLLOWING MRI-GUIDED PROSTATE BIOPSY
    Volume: 197 Page(s): E93 - E94
    04/01/2017 Authors: Liu W; Patil D; Howard D; Moore R; Wang H; Sanda M; Filson C
  • A PATIENT-CENTERED PRACTICE CHANGE: FINDING THE BEST APPROACH FOR PROSTATE CANCER DECISION SUPPORT
    Volume: 197 Page(s): E933 - E933
    04/01/2017 Authors: Berry D; Halpenny B; Underhill M; Sanda M; Master V; Filson C; Chang P; Chien G; Wolpin S
  • Targeted RNA Sequencing of FFPE Prostate Biopsies and Matched Prostatectomies
    Volume: 31
    04/01/2017 Authors: Sharma NV; Pellegrini KL; Osunkoya AO; Gillespie T; Petros J; Huang E; Sanda MG; Moreno CS
  • PREDICTORS OF PATIENT AND PARTNER REPORTED SEXUAL SATISFACTION FOLLOWING RADICAL PROSTATECTOMY
    Volume: 14 Page(s): E81 - E82
    02/01/2017 Authors: Mehta A; Patil D; Goodman M; Sanda MG
  • Relief of Urinary Symptom Burden after Primary Prostate Cancer Treatment.
    J Urol Volume: 197 Page(s): 376 - 384
    02/01/2017 Authors: Chang P; Regan MM; Ferrer M; Guedea F; Patil D; Wei JT; Hembroff LA; Michalski JM; Saigal CS; Litwin MS
  • Clinical Use of Expanded Prostate Cancer Index Composite for Clinical Practice to Assess Patient Reported Prostate Cancer Quality of Life Following Robot-Assisted Radical Prostatectomy.
    J Urol Volume: 197 Page(s): 109 - 114
    01/01/2017 Authors: Wagner AA; Cheng PJ; Carneiro A; Dovirak O; Khosla A; Taylor KN; Crociani CM; McAnally KC; Percy A; Dewey LE
  • Multinational Prospective Study of Patient-Reported Outcomes After Prostate Radiation Therapy: Detailed Assessment of Rectal Bleeding.
    Int J Radiat Oncol Biol Phys Volume: 96 Page(s): 770 - 777
    11/15/2016 Authors: Lee JY; Daignault-Newton S; Heath G; Scarlett S; Sanda MG; Chang P; Regan MM; Michalski JM; Sandler HM; Feng FY
  • Initial Report of NRG Oncology/RTOG 0232: A Phase 3 Study Comparing Combined External Beam Radiation and Transperineal Interstitial Permanent Brachytherapy With Brachytherapy Alone for Selected Patients With Intermediate-Risk Prostatic Carcinoma.
    Int J Radiat Oncol Biol Phys Volume: 96 Page(s): S4
    10/01/2016 Authors: Prestidge BR; Winter K; Sanda MG; Amin M; Bice WS; Michalski J; Ibbott GS; Crook JM; Catton CN; Gay HA
  • Erectile Dysfunction and Sexual Problems Two to Three Years After Prostatectomy Among American, Norwegian, and Spanish Patients.
    Clin Genitourin Cancer Volume: 14 Page(s): e265 - e273
    06/01/2016 Authors: Stors AH; Sanda MG; Boronat OG; Chang P; Patil D; Crociani C; Suarez JF; Cvancarova M; Loge JH; Foss SD
  • Gleason Misclassification Rate Is Independent of Number of Biopsy Cores in Systematic Biopsy.
    Urology Volume: 91 Page(s): 143 - 149
    05/01/2016 Authors: Quintana L; Ward A; Gerrin SJ; Genega EM; Rosen S; Sanda MG; Wagner AA; Chang P; DeWolf WC; Ye H
  • TARGETED SEQUENCING OF PROSTATE CANCER-ASSOCIATED RNAS IN EXTRACELLULAR VESICLES FROM POST-DRE URINE
    Volume: 195 Page(s): E12 - E13
    04/01/2016 Authors: Pellegrini K; Patil D; Douglas K; Wehrmeyer K; Bausum A; Torlak M; Sanda M; Moreno C
  • PCA3 AND T2: ERG ADD FURTHER PREDICTIVE AND CLINICAL BENEFIT TO THE DETECTION OF PROSTATE CANCER IN MEN OF VARIOUS AGES IN THE EARLY DETECTION RESEARCH NETWORK (EDRN)
    Volume: 195 Page(s): E249 - E250
    04/01/2016 Authors: O'Malley P; Golombos DM; Lewicki P; Al Awamlh BAH; Christos PJ; Thompson IM; Sanda MG; Wei JT; Rubin MA; Barbieri CE
  • Outcomes of Active Surveillance for Clinically Localized Prostate Cancer in the Prospective, Multi-Institutional Canary PASS Cohort.
    J Urol Volume: 195 Page(s): 313 - 320
    02/01/2016 Authors: Newcomb LF; Thompson IM; Boyer HD; Brooks JD; Carroll PR; Cooperberg MR; Dash A; Ellis WJ; Fazli L; Feng Z
  • Predicting return of erectile function following external beam radiotherapy or brachytherapy for prostate cancer using EPIC-CP.
    Volume: 34
    01/10/2016 Authors: Mihalcik SA; Chipman J; Sanda MG; Kaplan ID; Crociani C; Chang P
  • Pre-treatment nomogram to predict potency after treatment for localized prostate cancer
    Volume: 34
    01/10/2016 Authors: Zabell J; Sanda MG; Litwin MS; Suarez JF; Regan MM; Saigal C; Kwan L; Gao T; Rabah D; Klein EA
  • Dynamic correlation of serum C-reactive protein (CRP) levels with serum prostate-specific antigen (PSA) levels in patients with prostate cancer (PCa) on androgen deprivation therapy (ADT).
    Volume: 34
    01/10/2016 Authors: Kucuk O; Balci B; Liu Y; Zhang C; Yilmaz B; Atag E; Karaoglu A; Jani AB; Harris W; Carthon BC
  • RNA biomarkers to facilitate the identification of aggressive prostate cancer.
    Mol Aspects Med Volume: 45 Page(s): 37 - 46
    11/01/2015 Authors: Pellegrini KL; Sanda MG; Moreno CS
  • Impact of Rectal Bleeding on Quality of Life Measures After Prostate Radiation Therapy: Comparison of the EPIC-26 and EPIC-CP Instruments
    Volume: 93 Page(s): S201 - S201
    11/01/2015 Authors: Lee JY; Scarlett S; Daignault-Newton S; Sanda MG; Michalski JM; Sandler HM; Kuban DA; Zietman AL; Ciezki JP; Kaplan ID
  • Quality of life after primary treatment for localized prostate cancer: long-term considerations.
    Eur Urol Volume: 68 Page(s): 609 - 610
    10/01/2015 Authors: Alemozaffar M; Sanda MG
  • The transcription factor ERG increases expression of neurotransmitter receptors on prostate cancer cells.
    BMC Cancer Volume: 15 Page(s): 604
    08/27/2015 Authors: Kissick HT; On ST; Dunn LK; Sanda MG; Asara JM; Pellegrini KL; Noel JK; Arredouani MS
  • The role of active vaccination in cancer immunotherapy: lessons from clinical trials.
    Curr Opin Immunol Volume: 35 Page(s): 15 - 22
    08/01/2015 Authors: Kissick HT; Sanda MG
  • Patient-reported quality of life after stereotactic body radiotherapy (SBRT), intensity modulated radiotherapy (IMRT), and brachytherapy.
    Radiother Oncol Volume: 116 Page(s): 179 - 184
    08/01/2015 Authors: Evans JR; Zhao S; Daignault S; Sanda MG; Michalski J; Sandler HM; Kuban DA; Ciezki J; Kaplan ID; Zietman AL
  • Usability evaluation and adaptation of the e-health Personal Patient Profile-Prostate decision aid for Spanish-speaking Latino men.
    BMC Med Inform Decis Mak Volume: 15 Page(s): 56
    07/24/2015 Authors: Berry DL; Halpenny B; Bosco JLF; Bruyere J; Sanda MG
  • Multicenter Evaluation of the Prostate Health Index to Detect Aggressive Prostate Cancer in Biopsy Nave Men.
    J Urol Volume: 194 Page(s): 65 - 72
    07/01/2015 Authors: de la Calle C; Patil D; Wei JT; Scherr DS; Sokoll L; Chan DW; Siddiqui J; Mosquera JM; Rubin MA; Sanda MG
  • MULTI-CENTER PROSPECTIVE STUDY OF URINE RNA TESTING AS A STRATEGY FOR PROSTATE CANCER SCREENING: COLLABORATION BETWEEN UROLOGY, PRIMARY CARE, AND COMMUNITY OUTREACH
    Volume: 193 Page(s): E957 - E958
    04/01/2015 Authors: Patil D; de la Calle C; Weaver B; Leach R; Thompson I; Sokoll L; Chan D; Groskopf J; Carter JJ; Torlak M
  • MULTICENTER EVALUATION OF THE PROSTATE HEALTH INDEX (PHI) FOR DETECTION OF AGGRESSIVE PROSTATE CANCER IN BIOPSY-NAIVE MEN
    Volume: 193 Page(s): E956 - E957
    04/01/2015 Authors: de la Calle C; Patil D; Wei J; Scherr D; Sokoll L; Chan D; Siddiqui J; Mosquera JM; Rubin M; Sanda M
  • COMBINING URINE PCA3 AND TMPRSS2: ERG TESTS TO REFINE PROSTATE CANCER DETECTION - VALIDATION STUDY AND HEALTH ECONOMIC ANALYSIS
    Volume: 193 Page(s): E982 - E983
    04/01/2015 Authors: Sanda M; Feng Z; Wei J; Howard D; Rubin M; Groskopf J; Sokoll L; Chan D; Regan M; Patil D
  • The prostate health index selectively identifies clinically significant prostate cancer.
    J Urol Volume: 193 Page(s): 1163 - 1169
    04/01/2015 Authors: Loeb S; Sanda MG; Broyles DL; Shin SS; Bangma CH; Wei JT; Partin AW; Klee GG; Slawin KM; Marks LS
  • LOCATION OF DISEASE DOES NOT IMPACT PCA3'S ABILITY TO PREDICT CANCER ON BIOPSY
    Volume: 193 Page(s): E54 - E54
    04/01/2015 Authors: O'Malley P; Al Awamlh BAH; Nguyen DP; Sanda MG; Thompson IM; Wei JT; Lee R; Rubin MA; Barbieri CE; Hermann MP
  • REAL-WORLD USE OF EPIC FOR CLINICAL PRACTICE (EPIC-CP) TO ASSESS PATIENT-REPORTED PROSTATE CANCER QUALITY-OF-LIFE IN THE CLINICAL SETTING
    Volume: 193 Page(s): E1057 - E1057
    04/01/2015 Authors: Chang P; Carneiro A; Dovirak O; Taylor K; Crociani C; McAnally K; Percy A; Sanda MG; Wagner AA
  • CLINICAL OUTCOMES OF CONSERVATIVELY MANAGED PROSTATE CANCER AMONG AFRICAN AMERICAN MEN
    Volume: 193 Page(s): E28 - E28
    04/01/2015 Authors: Patel A; Sanda M; Patil D; Issa M; Petros J
  • Benchmarks for operative outcomes of robotic and open radical prostatectomy: results from the Health Professionals Follow-up Study.
    Eur Urol Volume: 67 Page(s): 432 - 438
    03/01/2015 Authors: Alemozaffar M; Sanda M; Yecies D; Mucci LA; Stampfer MJ; Kenfield SA
  • Real-world use of epic for clinical practice (EPIC-CP) to assess patient-reported prostate cancer quality of life in the clinical setting
    Volume: 33
    03/01/2015 Authors: Chang P; Carneiro A; Dovirak O; Taylor K; Crociani C; Sanda MG; Percy A; McAnally K; Wagner AA
  • Genomic RNAseq From Formalin Fixed Paraffin Embedded (FFPE) Prostate Needle Core Biopsies of Patients With Prostatic Adenocarcinoma
    Volume: 95 Page(s): 246A - 246A
    02/01/2015 Authors: Moreno C; Long Q; Sannigrahi S; Gillespie T; Petros J; Sanda M; Osunkoya A
  • Genomic RNAseq From Formalin Fixed Paraffin Embedded (FFPE) Prostate Needle Core Biopsies of Patients With Prostatic Adenocarcinoma
    Volume: 28 Page(s): 246A - 246A
    02/01/2015 Authors: Moreno C; Long Q; Sannigrahi S; Gillespie T; Petros J; Sanda M; Osunkoya A
  • Correlation of Urinary T2:ERG Fusion Detection and Tissue ERG Expression: Comprehensive Evaluation of Prostatectomy Specimens From the EDRN Study
    Volume: 95 Page(s): 220A - 220A
    02/01/2015 Authors: Fontugne J; Sanda M; Tomlins S; Wei J; Patil D; Ye H; Park K; Chipman J; Regan M; Scherr D
  • Correlation of Urinary T2:ERG Fusion Detection and Tissue ERG Expression: Comprehensive Evaluation of Prostatectomy Specimens From the EDRN Study
    Volume: 28 Page(s): 220A - 220A
    02/01/2015 Authors: Fontugne J; Sanda M; Tomlins S; Wei J; Patil D; Ye H; Park K; Chipman J; Regan M; Scherr D
  • Minimally important difference for the Expanded Prostate Cancer Index Composite Short Form.
    Urology Volume: 85 Page(s): 101 - 105
    01/01/2015 Authors: Skolarus TA; Dunn RL; Sanda MG; Chang P; Greenfield TK; Litwin MS; Wei JT; PROSTQA Consortium
  • Can urinary PCA3 supplement PSA in the early detection of prostate cancer?
    J Clin Oncol Volume: 32 Page(s): 4066 - 4072
    12/20/2014 Authors: Wei JT; Feng Z; Partin AW; Brown E; Thompson I; Sokoll L; Chan DW; Lotan Y; Kibel AS; Busby JE
  • Intense androgen-deprivation therapy with abiraterone acetate plus leuprolide acetate in patients with localized high-risk prostate cancer: results of a randomized phase II neoadjuvant study.
    J Clin Oncol Volume: 32 Page(s): 3705 - 3715
    11/20/2014 Authors: Taplin M-E; Montgomery B; Logothetis CJ; Bubley GJ; Richie JP; Dalkin BL; Sanda MG; Davis JW; Loda M; True LD
  • Prostate cancer with Paneth cell-like neuroendocrine differentiation has recognizable histomorphology and harbors AURKA gene amplification.
    Volume: 45 Page(s): 2136 - 2143
    10/01/2014 Authors: Park K; Chen Z; MacDonald TY; Siddiqui J; Ye H; Erbersdobler A; Shevchuk MM; Robinson BD; Sanda MG; Chinnaiyan AM
  • Early Quality of Life (QOL) Declines Correlate With Later QOL After Intensity Modulated Radiation Therapy, Low-Dose-Rate Brachytherapy, or Stereotactic Radiation for Prostate Cancer
    Volume: 90 Page(s): S84 - S85
    09/01/2014 Authors: Zhao S; Evans JR; Daignault-Newton S; Sanda MG; Michalski J; Sandler HM; Kuban DA; Ciezki JP; Kaplan ID; Zietman AL
  • Patient-Reported Outcomes for Quality of Life (QOL) by Expanded Prostate Cancer Index (EPIC) 15 Years Posttreatment
    Volume: 90 Page(s): S714 - S714
    09/01/2014 Authors: Zhou J; Daignault-Newton S; Miller D; Wei J; Dunn R; Johnson S; Jackson W; Imam H; Kazzi N; McLaughlin R
  • Comparative Effectiveness Analysis of Patient-Reported Quality of Life (QOL) After Stereotactic Body Radiation Therapy as Compared to Intensity Modulated Radiation Therapy or Low-Dose-Rate Brachytherapy up to 2 Years After Treatment
    Volume: 90 Page(s): S409 - S409
    09/01/2014 Authors: Evans JR; Zhao S; Daignault-Newton S; Sanda M; Michalski J; Sandler HM; Kuban DA; Ciezki JP; Kaplan ID; Zietman AL
  • Localized prostate cancer in Norway, the United States, and Spain: between-country differences of variables before treatment among patients eligible for curative treatment.
    Clin Genitourin Cancer Volume: 12 Page(s): e117 - e125
    08/01/2014 Authors: Stors AH; Sanda MG; Ferrer M; Loge JH; Dahl AA; Steinsvik EAS; Guedea F; Cvancarova M; Foss SD
  • Androgens alter T-cell immunity by inhibiting T-helper 1 differentiation.
    Proc Natl Acad Sci U S A Volume: 111 Page(s): 9887 - 9892
    07/08/2014 Authors: Kissick HT; Sanda MG; Dunn LK; Pellegrini KL; On ST; Noel JK; Arredouani MS
  • Recommended patient-reported core set of symptoms to measure in prostate cancer treatment trials.
    J Natl Cancer Inst Volume: 106
    07/01/2014 Authors: Chen RC; Chang P; Vetter RJ; Lukka H; Stokes WA; Sanda MG; Watkins-Bruner D; Reeve BB; Sandler HM
  • Recommended patient-reported core set of symptoms to measure in head and neck cancer treatment trials.
    J Natl Cancer Inst Volume: 106
    07/01/2014 Authors: Chera BS; Eisbruch A; Murphy BA; Ridge JA; Gavin P; Reeve BB; Bruner DW; Movsas B
  • Prostate Cancer Prevention Trial risk calculator 2.0 for the prediction of low- vs high-grade prostate cancer.
    Urology Volume: 83 Page(s): 1362 - 1367
    06/01/2014 Authors: Ankerst DP; Hoefler J; Bock S; Goodman PJ; Vickers A; Hernandez J; Sokoll LJ; Sanda MG; Wei JT; Leach RJ
  • Satisfaction with information used to choose prostate cancer treatment.
    J Urol Volume: 191 Page(s): 1265 - 1271
    05/01/2014 Authors: Gilbert SM; Sanda MG; Dunn RL; Greenfield TK; Hembroff L; Klein E; Saigal CS; Pisters L; Michalski J; Sandler HM
  • Comparative effectiveness study of patient-reported outcomes after proton therapy or intensity-modulated radiotherapy for prostate cancer.
    Cancer Volume: 120 Page(s): 1076 - 1082
    04/01/2014 Authors: Hoppe BS; Michalski JM; Mendenhall NP; Morris CG; Henderson RH; Nichols RC; Mendenhall WM; Williams CR; Regan MM; Chipman JJ
  • PREDICTORS OF FAVORABLE URINARY OUTCOMES AFTER PROSTATE CANCER TREATMENT
    Volume: 191 Page(s): E601 - E601
    04/01/2014 Authors: Chang P; Regan M; Wei J; Hembroff L; Michalski J; Saigal C; Litwin MS; Hamstra D; Kaplan I; Ciezki J
  • Measuring and predicting prostate cancer related quality of life changes using EPIC for clinical practice.
    J Urol Volume: 191 Page(s): 638 - 645
    03/01/2014 Authors: Chipman JJ; Sanda MG; Dunn RL; Wei JT; Litwin MS; Crociani CM; Regan MM; Chang P; PROST-QA Consortium
  • Molecular Subclasses of Prostate Cancer: A Comprehensive Evaluation of All Tumor Foci in Radical Prostatectomy Specimens
    Volume: 27 Page(s): 229A - 229A
    02/01/2014 Authors: Fontugne J; Ye H; Park K; Blattner M; Siddiqui J; MacDonald T; Chinnaiyan AM; Sanda M; Barbieri CE; Rubin MA
  • Molecular Subclasses of Prostate Cancer: A Comprehensive Evaluation of All Tumor Foci in Radical Prostatectomy Specimens
    Volume: 94 Page(s): 229A - 229A
    02/01/2014 Authors: Fontugne J; Ye H; Park K; Blattner M; Siddiqui J; MacDonald T; Chinnaiyan AM; Sanda M; Barbieri CE; Rubin MA
  • Dose to the inferior rectum is strongly associated with patient reported bowel quality of life after radiation therapy for prostate cancer.
    Radiother Oncol Volume: 110 Page(s): 291 - 297
    02/01/2014 Authors: Stenmark MH; Conlon ASC; Johnson S; Daignault S; Litzenberg D; Marsh R; Ritter T; Vance S; Kazzi N; Feng FY
  • Immunization with a peptide containing MHC class I and II epitopes derived from the tumor antigen SIM2 induces an effective CD4 and CD8 T-cell response.
    PLoS One Volume: 9 Page(s): e93231
    01/01/2014 Authors: Kissick HT; Sanda MG; Dunn LK; Arredouani MS
  • Development of a peptide-based vaccine targeting TMPRSS2:ERG fusion-positive prostate cancer.
    Cancer Immunol Immunother Volume: 62 Page(s): 1831 - 1840
    12/01/2013 Authors: Kissick HT; Sanda MG; Dunn LK; Arredouani MS
  • Neoadjuvant androgen deprivation therapy leads to immediate impairment of vitality/hormonal and sexual quality of life: results of a multicenter prospective study.
    Urology Volume: 82 Page(s): 1363 - 1368
    12/01/2013 Authors: Gay HA; Michalski JM; Hamstra DA; Wei JT; Dunn RL; Klein EA; Sandler HM; Saigal C; Litwin M; Kuban D
  • Re: Urinary TMPRSS2:ERG and PCA3 in an active surveillance cohort: results from a baseline analysis in the Canary Prostate Active Surveillance Study.
    J Urol Volume: 190 Page(s): 1764
    11/01/2013 Authors: Taneja SS
  • IMPROVING A TREATMENT DECISION SUPPORT SYSTEM FOR MINORITY MEN WITH LOCALIZED PROSTATE CANCER
    ONCOLOGY NURSING FORUM Volume: 40 Page(s): E433 - E433
    11/01/2013 Authors: Berry D; Sanda M; Chang P; Hayes J; Halpenny B
  • Survivorship after prostate cancer treatment: spouses' quality of life at 36 months.
    Oncol Nurs Forum Volume: 40 Page(s): 567 - 573
    11/01/2013 Authors: Harden J; Sanda MG; Wei JT; Yarandi HN; Hembroff L; Hardy J; Northouse L
  • Successful Patient Acceptance of Randomization Within the Pace Study (Prostate Advances in Comparative Evidence)
    Volume: 87 Page(s): S365 - S365
    10/01/2013 Authors: Tree A; Aluwini S; Bryant H; Hall E; Incrocci L; Kaplan I; Ostler P; Sanda M; Thompson A; van As N
  • Comparative Effectiveness Study of Proton Therapy Versus IMRT for Definitive Treatment of Prostate Cancer Based on Patient-Reported Outcomes
    Volume: 87 Page(s): S346 - S346
    10/01/2013 Authors: Hoppe BS; Michalski JM; Mendenhall NP; Morris CG; Henderson RH; Nichols RC; Regan MM; Sandler HM; Sanda MG; Hamstra DA
  • Patient-Reported Quality of Life Outcomes in Intermediate-Risk Prostate Cancer Patients Treated With Stereotactic Body Radiation Therapy
    Volume: 87 Page(s): S25 - S25
    10/01/2013 Authors: Meier R; Kaplan I; Beckman A; Henning G; Woodhouse S; Williamson S; Mohideen N; Herold D; Cotrutz C; Sanda M
  • Dose to the Inferior Rectum Ha's the Strongest Association With Patient-Reported Bowel. Quality of Life(QOL) After External Beam Radiation Therapy (EBRT) for Prostate Cancer
    Volume: 87 Page(s): S172 - S172
    10/01/2013 Authors: Stenmark MH; Johnson S; Conlon AS; Dainault S; Marsh R; Ritter T; Litzenberg D; Sandler HM; Sanda MG; Hamstra DA
  • Diagnosis of relevant prostate cancer using supplementary cores from magnetic resonance imaging-prompted areas following multiple failed biopsies.
    Magn Reson Imaging Volume: 31 Page(s): 947 - 952
    07/01/2013 Authors: Costa DN; Bloch BN; Yao DF; Sanda MG; Ngo L; Genega EM; Pedrosa I; DeWolf WC; Rofsky NM
  • Multi-institutional prospective evaluation of bowel quality of life after prostate external beam radiation therapy identifies patient and treatment factors associated with patient-reported outcomes: the PROSTQA experience.
    Int J Radiat Oncol Biol Phys Volume: 86 Page(s): 546 - 553
    07/01/2013 Authors: Hamstra DA; Conlon ASC; Daignault S; Dunn RL; Sandler HM; Hembroff AL; Zietman AL; Kaplan I; Ciezki J; Kuban DA
  • Combining urinary detection of TMPRSS2:ERG and PCA3 with serum PSA to predict diagnosis of prostate cancer.
    Urol Oncol Volume: 31 Page(s): 566 - 571
    07/01/2013 Authors: Salami SS; Schmidt F; Laxman B; Regan MM; Rickman DS; Scherr D; Bueti G; Siddiqui J; Tomlins SA; Wei JT
  • Urinary TMPRSS2:ERG and PCA3 in an active surveillance cohort: results from a baseline analysis in the Canary Prostate Active Surveillance Study.
    Clin Cancer Res Volume: 19 Page(s): 2442 - 2450
    05/01/2013 Authors: Lin DW; Newcomb LF; Brown EC; Brooks JD; Carroll PR; Feng Z; Gleave ME; Lance RS; Sanda MG; Thompson IM
  • Patient-reported outcomes after 3-dimensional conformal, intensity-modulated, or proton beam radiotherapy for localized prostate cancer.
    Cancer Volume: 119 Page(s): 1729 - 1735
    05/01/2013 Authors: Gray PJ; Paly JJ; Yeap BY; Sanda MG; Sandler HM; Michalski JM; Talcott JA; Coen JJ; Hamstra DA; Shipley WU
  • Prospective multicenter evaluation of the Beckman Coulter Prostate Health Index using WHO calibration.
    J Urol Volume: 189 Page(s): 1702 - 1706
    05/01/2013 Authors: Loeb S; Sokoll LJ; Broyles DL; Bangma CH; van Schaik RHN; Klee GG; Wei JT; Sanda MG; Partin AW; Slawin KM
  • Androgens modulate anti-tumor immunity through interference with the T lymphocyte differentiation program
    Volume: 190
    05/01/2013 Authors: Arredouani MS; Kissick H; Dunn L; Sanda M
  • PROSTATE HEALTH INDEX (PHI) FOR REDUCING OVERDETECTION OF INDOLENT PROSTATE CANCER AND UNNECESSARY BIOPSY WHILE IMPROVING DETECTION OF AGGRESSIVE CANCERS
    Volume: 189 Page(s): E843 - E843
    04/01/2013 Authors: Sanda M; Wei J; Broyles D; Shin S; Partin A; Klee G; Bangma C; Slawin K; Marks L; Cruz A
  • NOMOGRAM PREDICTING URINARY INCONTINENCE FOR MEN WITH LOCALIZED PROSTATE CANCER TREATED BY RADICAL PROSTATECTOMY, EXTERNAL-BEAM RADIOTHERAPY, AND BRACHYTHERAPY
    Volume: 189 Page(s): E178 - E179
    04/01/2013 Authors: Klink J; Sanda M; Litwin M; Ferrer M; Regan M; Saigal C; Kwan L; Gao T; Rabah D; Klein E
  • EFFECT OF NEOADJUVANT ABIRATERONE ACETATE PLUS LEUPROLIDE ACETATE ON PSA, PATHOLOGIC RESPONSE, AND INTRAPROSTATIC/SERUM ANDROGEN LEVELS IN LOCALIZED HIGH-RISK PROSTATE CANCER: RESULTS OF A RANDOMIZED PHASE 2 STUDY
    Volume: 189 Page(s): E272 - E272
    04/01/2013 Authors: Richie JP; Montgomery RB; Logothetis CJ; Bubley GJ; Dalkin BL; Sanda MG; Loda MF; Lis RT; True LD; Troncoso P
  • Uncertainty and perception of danger among patients undergoing treatment for prostate cancer.
    BJU Int Volume: 111 Page(s): E84 - E91
    03/01/2013 Authors: Kazer MW; Bailey DE; Chipman J; Psutka SP; Hardy J; Hembroff L; Regan M; Dunn RL; Crociani C; Sanda MG
  • Association of declining PSA values with a lower risk of progression in the Canary Prostate Cancer Active Surveillance Study (PASS).
    J Clin Oncol Volume: 31 Page(s): 88
    02/20/2013 Authors: Brown EC; Cooperberg MR; Newcomb LF; Carroll P; Feng Z; Gleave ME; Lance R; Sanda MG; Thompson IM; Wei JT
  • Association of declining PSA values with a lower risk of progression in the Canary Prostate Cancer Active Surveillance Study (PASS)
    Volume: 31
    02/20/2013 Authors: Brooks JD; Brown EC; Cooperberg MR; Newcomb LF; Carroll P; Feng Z; Gleave ME; Lance R; Sanda MG; Thompson IM
  • Prediction of patient-reported bowel quality of life (QOL) after dose-escalated radiation therapy (RT) for prostate cancer by rectal dosimetry.
    Volume: 31 Page(s): 84
    02/20/2013 Authors: Conlon ASC; Daignault S; Bassetti MF; Vance S; Marsh R; Litzenberg D; Ritter T; Feng FY-C; Sandler HM; Sanda MG
  • Partners' long-term appraisal of their caregiving experience, marital satisfaction, sexual satisfaction, and quality of life 2 years after prostate cancer treatment.
    Cancer Nurs Volume: 36 Page(s): 104 - 113
    01/01/2013 Authors: Harden JK; Sanda MG; Wei JT; Yarandi H; Hembroff L; Hardy J; Northouse LL; PROSTQA Consortium Study Group
  • Nomogram predicting treatment- related bowel dysfunction for men with localized prostate cancer treated by radical prostatectomy (RP), external-beam radiotherapy (EBRT), and brachytherapy (PI)
    JOURNAL OF CLINICAL ONCOLOGY Volume: 30
    12/01/2012 Authors: Klink JC; Michalski JM; Sanda MG; Litwin MS; Ferrer M; Hamstra DA; Regan MM; Saigal C; Kwan L; Gao T
  • Nomogram predicting treatment-related sexual dysfunction for men with localized prostate cancer treated by radical prostatectomy (RP), external-beam radiotherapy (EBRT), and brachytherapy (PI)
    JOURNAL OF CLINICAL ONCOLOGY Volume: 30
    12/01/2012 Authors: Klink JC; Sanda MG; Litwin MS; Ferrer M; Regan MM; Saigal C; Kwan L; Gao T; Klein EA; Kattan MW
  • Nomogram predicting treatment-related urinary incontinence for men with localized prostate cancer treated by radical prostatectomy (RP), external-beam radiotherapy (EBRT), or brachytherapy (PI)
    JOURNAL OF CLINICAL ONCOLOGY Volume: 30
    12/01/2012 Authors: Klink JC; Sanda MG; Litwin MS; Ferrer M; Regan MM; Saigal C; Kwan L; Gao T; Klein EA; Kattan MW
  • Patient-reported Quality of Life in Prostate Cancer Patients Treated With 3D Conformal Intensity Modulated or Proton Beam Radiation Therapy
    Volume: 84 Page(s): S13 - S13
    11/01/2012 Authors: Gray PJ; Paly JJ; Yeap B; Sanda MG; Talcott JA; Sandler HM; Michalski JM; Hamstra DA; Bekelman JE; Efstathiou JA
  • Stereotactic Body Radiation Therapy for Intermediate-risk Organ-confined Prostate Cancer: Interim Toxicity and Quality of Life Outcomes From a Multi-institutional Study
    Volume: 84 Page(s): S148 - S148
    11/01/2012 Authors: Meier R; Kaplan I; Beckman A; Henning G; Woodhouse S; Williamson S; Mohideen N; Herold D; Cotrutz C; Sanda M
  • Prediction of prostate cancer extracapsular extension with high spatial resolution dynamic contrast-enhanced 3-T MRI.
    Eur Radiol Volume: 22 Page(s): 2201 - 2210
    10/01/2012 Authors: Bloch BN; Genega EM; Costa DN; Pedrosa I; Smith MP; Kressel HY; Ngo L; Sanda MG; Dewolf WC; Rofsky NM
  • The TMPRSS2:ERG rearrangement, ERG expression, and prostate cancer outcomes: a cohort study and meta-analysis.
    Cancer Epidemiol Biomarkers Prev Volume: 21 Page(s): 1497 - 1509
    09/01/2012 Authors: Pettersson A; Graff RE; Bauer SR; Pitt MJ; Lis RT; Stack EC; Martin NE; Kunz L; Penney KL; Ligon AH
  • Evaluation of patient-reported quality-of-life outcomes after renal surgery.
    Urology Volume: 79 Page(s): 1268 - 1273
    06/01/2012 Authors: Kim SB; Williams SB; Cheng S-C; Sanda MG; Wagner AA
  • Selective detection of histologically aggressive prostate cancer: an Early Detection Research Network Prediction model to reduce unnecessary prostate biopsies with validation in the Prostate Cancer Prevention Trial.
    Cancer Volume: 118 Page(s): 2651 - 2658
    05/15/2012 Authors: Williams SB; Salami S; Regan MM; Ankerst DP; Wei JT; Rubin MA; Thompson IM; Sanda MG
  • Distinct transcriptome of regulatory T cells in prostate cancer
    Volume: 188
    05/01/2012 Authors: Arredouani MS; Kissick H; Dunn L; Sanda M
  • Metabolic profiling of T-cell differentiation and tolerance
    Volume: 188
    05/01/2012 Authors: Kissick H; Finke J; Dunn L; Asara J; Sanda M; Arredouani MS
  • Immunogenic Peptides Derived from the Transcription Factor ERG as a Vaccine for Prostate Cancer
    Volume: 188
    05/01/2012 Authors: Kissick H; Dunn L; Lu B; Sanda M; Arredouani MS
  • Breaking immune tolerance to prostate-associated tumor antigens through Tim-1 receptor
    Volume: 188
    05/01/2012 Authors: Arredouani MS; Kissick H; Dunn L; Strom T; Sanda M
  • Identification of functionally active, low frequency copy number variants at 15q21.3 and 12q21.31 associated with prostate cancer risk.
    Proc Natl Acad Sci U S A Volume: 109 Page(s): 6686 - 6691
    04/24/2012 Authors: Demichelis F; Setlur SR; Banerjee S; Chakravarty D; Chen JYH; Chen CX; Huang J; Beltran H; Oldridge DA; Kitabayashi N
  • The NCI Early Detection Research Network (EDRN) urinary PCA3 validation trial
    CANCER RESEARCH Volume: 72
    04/15/2012 Authors: Wei JT; Sanda MG; Thompson IM; Partin A; Feng Z; Sokoll L; Groskopf J; Brown E; Lotan Y; Kibel A
  • THE EXPANDED PROSTATE CANCER INDEX COMPOSITE FOR CLINICAL PRACTICE (EPIC-CP) IS SENSITIVE TO TREATMENT-RELATED QUALITY OF LIFE CHANGES OVER TIME: VALIDATION USING THE PROST-QA COHORT
    Volume: 187 Page(s): E458 - E459
    04/01/2012 Authors: Chang P; Chipman J; Regan M; Wei J; Dunn R; Litwin M; Sanda M
  • PROGRESSION AND TREATMENT IN A MULTI-INSTITUTIONAL, PROSPECTIVE ACTIVE SURVEILLANCE STUDY: RESULTS FROM CANARY PROSTATE ACTIVE SURVEILLANCE STUDY (PASS)
    Volume: 187 Page(s): E403 - E403
    04/01/2012 Authors: Lin D; Newcomb L; Ellis W; Gleave M; Thompson I; Brooks J; Nelson P; Sanda M; Lance R; Wei J
  • THE NCI EARLY DETECTION RESEARCH NETWORK (EDRN) URINARY PCA3 VALIDATION TRIAL
    Volume: 187 Page(s): E889 - E890
    04/01/2012 Authors: Wei J; Sanda M; Thompson I; Partin A; Feng Z; Sokoll L; Groskopf J; Brown E; Lotan Y; Kibel A
  • ALLEVIATION VERSUS INDUCTION OF URINARY OBSTRUCTION OR INCONTINENCE BY PROSTATE CANCER TREATMENT: THE PIVOTAL ROLE OF PRETREATMENT URINARY SYMPTOMS
    Volume: 187 Page(s): E283 - E283
    04/01/2012 Authors: Chang P; Regan M; Stephenson A; Ferrer M; Wei J; Hembroff L; Francisco Suarez J; Michalski J; Saigal C; Litwin M
  • INCORPORATION OF BODY MASS INDEX AND PROSTATE SIZE INTO A NOMOGRAM FOR SELECTING PATIENTS FOR INITIAL PROSTATE BIOPSY: VALIDATION IN THE PROSTATE CANCER PREVENTION TRIAL
    Volume: 187 Page(s): E493 - E493
    04/01/2012 Authors: Salami S; Regan M; Wei J; Ankerst D; Williams S; Scherr D; Bueti G; Siddiqui J; DeWolf W; Kearney M
  • SURGEON VARIANCE IN PATIENT-REPORTED AND CLINICAL OUTCOMES OF RETROPUBIC, LAPAROSCOPIC, OR ROBOTIC RADICAL PROSTATECTOMY
    Volume: 187 Page(s): E732 - E732
    04/01/2012 Authors: Sanda M; Chipman J; Wei J; Hembroff L; Hollenbeck B; Wood D; Saigal C; Litwin M; Hu J; Dahl D
  • Urinary TMPRSS2: Use of ERG and PCA3 to predict tumor volume and Gleason grade in an active surveillance cohort-Results from the Canary/EDRN Prostate Active Surveillance Study
    JOURNAL OF CLINICAL ONCOLOGY Volume: 30
    02/10/2012 Authors: Lin DW; Newcomb LF; Brown EC; Brooks JD; Carroll P; Feng Z; Gleave ME; Lance R; Sanda MG; Thompson IM
  • Urinary TMPRSS2: Use of ERG and PCA3 to predict tumor volume and Gleason grade in an active surveillance cohort-Results from the Canary/EDRN Prostate Active Surveillance Study.
    J Clin Oncol Volume: 30 Page(s): 2
    02/10/2012 Authors: Lin DW; Newcomb LF; Brown EC; Brooks JD; Carroll P; Feng Z; Gleave ME; Lance R; Sanda MG; Thompson IM
  • Bowel and bladder toxicity patterns in patients with prostate cancer treated with proton beam versus intensity-modulated radiation therapy.
    J Clin Oncol Volume: 30 Page(s): 22
    02/10/2012 Authors: Gray PJ; Paly JJ; Sanda MG; Sandler HM; Michalski JM; Talcott JA; Coen J; Shipley WU; Zietman AL; Bekelman JE
  • Bowel and bladder toxicity patterns in patients with prostate cancer treated with proton beam versus intensity-modulated radiation therapy
    JOURNAL OF CLINICAL ONCOLOGY Volume: 30
    02/10/2012 Authors: Gray PJ; Paly JJ; Sanda MG; Sandler HM; Michalski JM; Talcott JA; Coen J; Shipley WU; Zietman AL; Bekelman JE
  • Evaluation of Novel ERG/SPINK1 IHC and 4-Color Quantum-Dot Based ERG/PTEN FISH in Radical Prostatectomy Specimens
    Volume: 25 Page(s): 233A - 233A
    02/01/2012 Authors: Park K; Palanisamy N; MacDonald T; Siddiqui J; Chinnaiyan AM; Sanda MG; Ye H; Rubin MA; Mosquera JM
  • Outcomes session.
    Urol Oncol Volume: 30 Page(s): 952 - 955
    01/01/2012 Authors: Penson DF; Barocas DA; Fleshner N; Sanda MG; Greenfield S
  • Updating risk prediction tools: a case study in prostate cancer.
    Biom J Volume: 54 Page(s): 127 - 142
    01/01/2012 Authors: Ankerst DP; Koniarski T; Liang Y; Leach RJ; Feng Z; Sanda MG; Partin AW; Chan DW; Kagan J; Sokoll L
  • Watchful waiting and quality of life among prostate cancer survivors in the Physicians' Health Study.
    J Urol Volume: 186 Page(s): 1862 - 1867
    11/01/2011 Authors: Kasperzyk JL; Shappley WV; Kenfield SA; Mucci LA; Kurth T; Ma J; Stampfer MJ; Sanda MG
  • Racial/ethnic differences in receipt of pelvic lymph node dissection among men with localized/regional prostate cancer.
    Cancer Volume: 117 Page(s): 4651 - 4658
    10/15/2011 Authors: Hayn MH; Orom H; Shavers VL; Sanda MG; Glasgow M; Mohler JL; Underwood W
  • Prediction of erectile function following treatment for prostate cancer.
    JAMA Volume: 306 Page(s): 1205 - 1214
    09/21/2011 Authors: Alemozaffar M; Regan MM; Cooperberg MR; Wei JT; Michalski JM; Sandler HM; Hembroff L; Sadetsky N; Saigal CS; Litwin MS
  • Expanded prostate cancer index composite for clinical practice: development and validation of a practical health related quality of life instrument for use in the routine clinical care of patients with prostate cancer.
    J Urol Volume: 186 Page(s): 865 - 872
    09/01/2011 Authors: Chang P; Szymanski KM; Dunn RL; Chipman JJ; Litwin MS; Nguyen PL; Sweeney CJ; Cook R; Wagner AA; DeWolf WC
  • An Internet intervention for management of uncertainty during active surveillance for prostate cancer.
    Oncol Nurs Forum Volume: 38 Page(s): 561 - 568
    09/01/2011 Authors: Kazer MW; Bailey DE; Sanda M; Colberg J; Kelly WK
  • Urine TMPRSS2:ERG fusion transcript stratifies prostate cancer risk in men with elevated serum PSA.
    Sci Transl Med Volume: 3 Page(s): 94ra72
    08/03/2011 Authors: Tomlins SA; Aubin SMJ; Siddiqui J; Lonigro RJ; Sefton-Miller L; Miick S; Williamsen S; Hodge P; Meinke J; Blase A
  • The experiences of unpartnered men with prostate cancer: a qualitative analysis.
    J Cancer Surviv Volume: 5 Page(s): 132 - 141
    06/01/2011 Authors: Kazer MW; Harden J; Burke M; Sanda MG; Hardy J; Bailey DE; PROSTQA Study Group
  • A multicenter study of [-2]pro-prostate specific antigen combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to 10.0 ng/ml prostate specific antigen range.
    J Urol Volume: 185 Page(s): 1650 - 1655
    05/01/2011 Authors: Catalona WJ; Partin AW; Sanda MG; Wei JT; Klee GG; Bangma CH; Slawin KM; Marks LS; Loeb S; Broyles DL
  • BENCHMARKS FOR OPERATIVE OUTCOMES OF ROBOTIC LAPAROSCOPIC AND OPEN RADICAL PROSTATECTOMY BASED ON RESULTS FROM A NATIONWIDE AMERICAN COHORT: THE HEALTH PROFESSIONALS FOLLOW-UP STUDY
    Volume: 185 Page(s): E715 - E715
    04/01/2011 Authors: Alemozaffar M; Sanda M; Yecies D; Stampfer M; Kenfield S
  • INTERNET-BASED EVALUATION OF QUALITY-OF-LIFE OUTCOMES AFTER ROBOTIC, LAPAROSCOPIC, AND OPEN RADICAL OR PARTIAL NEPHRECTOMY
    Volume: 185 Page(s): E433 - E433
    04/01/2011 Authors: Kim SB; Cheng S-C; Mongiu AK; Sanda MG; Wagner AA
  • EVALUATION OF THE PROSTATE HEALTH INDEX (PHI)(1) IN THE 2 TO 4, AND 4 TO 10 NG/ML PSA RANGES: RESULTS FROM A MULTI-SITE, PROSPECTIVE, CLINICAL EVALUATION
    Volume: 185 Page(s): E396 - E396
    04/01/2011 Authors: Catalona WJ; Sanda MG; Wei JT; Klee GG; Bangma CH; Slawin KM; Marks LS; Loeb S; Broyles DL; Shin SS
  • PERSONALIZED PREDICTION OF ERECTION RECOVERY AFTER PRIMARY PROSTATE CANCER TREATMENT: VALIDATION IN THE COMMUNITY-BASED CAPSURE COHORT OF A PREDICTIVE MODEL DEVELOPED IN PROSTQA
    Volume: 185 Page(s): E616 - E617
    04/01/2011 Authors: Alemozaffar M; Sanda M; Sadetsky N; Regan M; Carroll P; Cooperberg M
  • Evaluation of the SCA instrument for measuring patient satisfaction with cancer care administered via paper or via the Internet.
    Ann Oncol Volume: 22 Page(s): 723 - 729
    03/01/2011 Authors: Kamo N; Dandapani SV; Miksad RA; Houlihan MJ; Kaplan I; Regan M; Greenfield TK; Sanda MG
  • The role of the transcription factor SIM2 in prostate cancer.
    PLoS One Volume: 6 Page(s): e28837
    01/01/2011 Authors: Lu B; Asara JM; Sanda MG; Arredouani MS
  • Development and validation of an abbreviated version of the expanded prostate cancer index composite instrument for measuring health-related quality of life among prostate cancer survivors.
    Urology Volume: 76 Page(s): 1245 - 1250
    11/01/2010 Authors: Szymanski KM; Wei JT; Dunn RL; Sanda MG
  • Editorial comment. Acute lower urinary tract symptoms after prostate brachytherapy with cesium-131.
    Urology Volume: 76 Page(s): 1148
    11/01/2010 Authors: Sanda MG
  • Urinary obstructive problems exposed but hormonal health-related quality-of-life concerns eschewed in prostate cancer quality-of-life study.
    J Clin Oncol Volume: 28 Page(s): 4667 - 4668
    11/01/2010 Authors: Sanda MG
  • Comparison of validated instruments measuring sexual function in men.
    Urology Volume: 76 Page(s): 380 - 386
    08/01/2010 Authors: Levinson AW; Ward NT; Sanda MG; Mettee LZ; Wei JT; Su L-M; Litwin MS; Pavlovich CP
  • Defective NKT cell activation by CD1d+ TRAMP prostate tumor cells is corrected by interleukin-12 with -galactosylceramide.
    PLoS One Volume: 5 Page(s): e11311
    06/25/2010 Authors: Nowak M; Arredouani MS; Tun-Kyi A; Schmidt-Wolf I; Sanda MG; Balk SP; Exley MA
  • Androgen ablation augments human HLA2.1-restricted T cell responses to PSA self-antigen in transgenic mice.
    Prostate Volume: 70 Page(s): 1002 - 1011
    06/15/2010 Authors: Arredouani MS; Tseng-Rogenski SS; Hollenbeck BK; Escara-Wilke J; Leander KR; Defeo-Jones D; Hwang C; Sanda MG
  • A prospective, multicenter, National Cancer Institute Early Detection Research Network study of [-2]proPSA: improving prostate cancer detection and correlating with cancer aggressiveness.
    Cancer Epidemiol Biomarkers Prev Volume: 19 Page(s): 1193 - 1200
    05/01/2010 Authors: Sokoll LJ; Sanda MG; Feng Z; Kagan J; Mizrahi IA; Broyles DL; Partin AW; Srivastava S; Thompson IM; Wei JT
  • The 'CaP Calculator': an online decision support tool for clinically localized prostate cancer.
    BJU Int Volume: 105 Page(s): 1417 - 1422
    05/01/2010 Authors: Katz MS; Efstathiou JA; D'Amico AV; Kattan MW; Sanda MG; Nguyen PL; Smith MR; Carroll PR; Zietman AL
  • Reduction in patient-reported acute morbidity in prostate cancer patients treated with 81-Gy Intensity-modulated radiotherapy using reduced planning target volume margins and electromagnetic tracking: assessing the impact of margin reduction study.
    Urology Volume: 75 Page(s): 1004 - 1008
    05/01/2010 Authors: Sandler HM; Liu P-Y; Dunn RL; Khan DC; Tropper SE; Sanda MG; Mantz CA
  • EVALUATION OF [-2]PROPSA IN COMBINATION WITH PSA AND FREE PSA, USING THE BECKMAN COULTER ACCESS IMMUNOASSAY SYSTEMS, FOR IDENTIFYING PATIENTS WITH AGGRESSIVE PROSTATE CANCER. A MULTI-CENTER PROSPECTIVE CLINICAL EVALUATION.
    Volume: 183 Page(s): E56 - E56
    04/01/2010 Authors: Catalona WJ; Sanda MG; Wei JT; Klee GG; Slawin KM; Marks LS; Bangma CH; Chan DW; Sokoll LJ; Roberts WL
  • [-2]PROPSA IN COMBINATION WITH PSA AND FREE-PSA, USING THE BECKMAN COULTER ACCESS IMMUNOASSAY SYSTEMS IMPROVES PROSTATE CANCER DETECTION RELATIVE TO PSA AND FREE PSA. A MULTI-CENTER PROSPECTIVE CLINICAL STUDY.
    Volume: 183 Page(s): E717 - E717
    04/01/2010 Authors: Catalona WJ; Sanda MG; Wei JT; Klee GG; Slawin KM; Marks LS; Bangma CH; Chan DW; Sokoll LJ; Roberts WL
  • COMBINING TMPRSS2: ERG AND PCA3 IN POST-DRE URINE WITH SERUM PSA TO IDENTIFY PROSTATE BIOPSY CANDIDATES: DEVELOPMENT AND VERIFICATION OF A CLINICALLY PRACTICAL ALGORITHM
    Volume: 183 Page(s): E839 - E839
    04/01/2010 Authors: Tomlins S; Sanda M; Salami S; Laxman B; Regan M; Siddiqui J; Rickman D; Scherr D; Rubin M; Wei J
  • Exploiting the Good Guys: Th1 Antiviral & Antitumor Human & Mouse NKT Cells
    Volume: 135 Page(s): S34 - S34
    01/01/2010 Authors: Exley M; Nowak M; Yue S; Scheuplein F; Arredouani MS; Sanda M; Sasada T; Balk S
  • Validation in a multiple urology practice cohort of the Prostate Cancer Prevention Trial calculator for predicting prostate cancer detection.
    J Urol Volume: 182 Page(s): 2653 - 2658
    12/01/2009 Authors: Eyre SJ; Ankerst DP; Wei JT; Nair PV; Regan MM; Bueti G; Tang J; Rubin MA; Kearney M; Thompson IM
  • Androgen Ablation Augments Cellular Immune Responses to PSA in a Humanized PSA/HLA-A2.1 Transgenic Mouse Model
    Volume: 32 Page(s): 966 - 966
    11/01/2009 Authors: Arredouani MS; Tseng-Rogenski S; Hollenbeck B; Defeo-Jones D; Hwang C; Sanda MG
  • Detection of TMPRSS2-ERG fusion gene expression in prostate cancer specimens by a novel assay using branched DNA.
    Urology Volume: 74 Page(s): 1156 - 1161
    11/01/2009 Authors: Lu B; Maqsodi B; Yang W; McMaster GK; Perner S; Regan M; Bubley GJ; Balk SP; Rubin M; Sanda MG
  • A Branched DNA Assay for Detecting TMPRSS2-ERG Fusions.
    Urology Volume: 74 Page(s): 1162
    11/01/2009 Authors: Sanda MG
  • Prospective study of determinants and outcomes of deferred treatment or watchful waiting among men with prostate cancer in a nationwide cohort.
    J Clin Oncol Volume: 27 Page(s): 4980 - 4985
    10/20/2009 Authors: Shappley WV; Kenfield SA; Kasperzyk JL; Qiu W; Stampfer MJ; Sanda MG; Chan JM
  • Prostate cancer screening and surveillance.
    JAMA Volume: 302 Page(s): 1529
    10/14/2009 Authors: Rogers CS
  • Further perspectives on treating localized prostate cancer.
    Oncology (Williston Park) Volume: 23 Page(s): 964 - 966
    10/01/2009 Authors: Aronovitz JA; Sanda MG
  • Brachytherapy or Surgery? A Composite View Further Perspectives on Treating Localized Prostate Cancer The Ciezki/Klein Article Reviewed
    ONCOLOGY-NEW YORK Volume: 23 Page(s): 964 - 966
    10/01/2009 Authors: Aronovitz JA; Sanda MG
  • Identification of the transcription factor single-minded homologue 2 as a potential biomarker and immunotherapy target in prostate cancer.
    Clin Cancer Res Volume: 15 Page(s): 5794 - 5802
    09/15/2009 Authors: Arredouani MS; Lu B; Bhasin M; Eljanne M; Yue W; Mosquera J-M; Bubley GJ; Li V; Rubin MA; Libermann TA
  • Prevalence of TMPRSS2-ERG fusion prostate cancer among men undergoing prostate biopsy in the United States.
    Clin Cancer Res Volume: 15 Page(s): 4706 - 4711
    07/15/2009 Authors: Mosquera J-M; Mehra R; Regan MM; Perner S; Genega EM; Bueti G; Shah RB; Gaston S; Tomlins SA; Wei JT
  • Expanded Prostate Cancer Index Composite Versus Incontinence Symptom Index and Sexual Health Inventory for Men to Measure Functional Outcomes After Prostatectomy EDITORIAL COMMENT
    JOURNAL OF UROLOGY Volume: 182 Page(s): 228 - 228
    07/01/2009 Authors: Sanda MG
  • Editorial comment. Nerve sparing during radical prostatectomy is associated with better recovery of urinary continence.
    Urology Volume: 73 Page(s): 1340 - 1341
    06/01/2009 Authors: Sanda MG
  • A 64-year-old man with low-risk prostate cancer: review of prostate cancer treatment.
    JAMA Volume: 301 Page(s): 2141 - 2151
    05/27/2009 Authors: Sanda MG; Kaplan ID
  • DISCERNING RISK OF CLINICALLY SIGNIFICANT VERSUS INDOLENT PROSTATE CANCER PRIOR TO BIOPSY: PREDICTIVE MODEL FROM A MULTI-CENTER COHORT
    Volume: 181 Page(s): 774 - 774
    04/01/2009 Authors: Williams SB; Regan MM; Wei JT; Kearney M; DeWolf WC; Tang J; Bueti G; Rubin M; Genega E; Eyre A
  • Live longer but not better...yet.
    Lancet Oncol Volume: 10 Page(s): 313 - 314
    04/01/2009 Authors: Sanda MG
  • UTILIZATION OF MEDICATIONS AND DEVICES FOR ERECTILE DYSFUNCTION AFTER PROSTATE CANCER TREATMENT: RESULTS FROM THE MULTICENTER PROSTQA CONSORTIUM
    Volume: 181 Page(s): 370 - 370
    04/01/2009 Authors: Sanda MG; Regan MM; Dunn RL; Michalski J; Kibel AS; Sandler HM; Saigal CS; Hembroff L; Klein EA; Ciezki JP
  • PREDICTING URINARY FUNCTION AFTER PROSTATE CANCER TREATMENT: A MULTIVARIABLE NOMOGRAM FROM THE PROSTQA CONSORTIUM
    Volume: 181 Page(s): 758 - 758
    04/01/2009 Authors: Sanda MG; Regan MM; Dunn RL; Michalski J; Kibel AS; Sandler HM; Litwin MS; Saigal CS; Hembroff L; Klein EA
  • INCREASED POSITIVE YIELD OF CLINICALLY SIGNIFICANT PROSTATE CANCER WITH MRI PROMPTED BIOPSIES
    Volume: 181 Page(s): 782 - 783
    04/01/2009 Authors: Yao DF; DeWdlf WC; Sanda MG; Bloch BN; Genega EM; Berry AM; Ngo L; Rofsky NM
  • [-2]PROPSA FOR PROSTATE CANCER DETECTION: A PROSPECTIVE, MULTICENTER, NCI EARLY DETECTION RESEARCH NETWORK STUDY
    Volume: 181 Page(s): 772 - 772
    04/01/2009 Authors: Sokoll LJ; Liu Y; Feng Z; Kagan J; Partin AW; Srivastava S; Thompson IM; Antonio S; Wei JT; Elliott D
  • PREDICTING ERECTION RECOVERY AFTER PROSTATECTOMY: A MULTIVARIABLE NOMOGRAM FROM THE PROSTQA CONSORTIUM
    Volume: 181 Page(s): 759 - 759
    04/01/2009 Authors: Sanda MG; Regan MM; Dunn RL; Kibel AS; Saigal CS; Litwin MS; Klein EA; Pisters LL; Wood DP; Hollenbeck BK
  • Health-related quality-of-life effects of watchful waiting re-evaluated in SPCG-4.
    Nat Clin Pract Urol Volume: 6 Page(s): 124 - 125
    03/01/2009 Authors: McDermott DW; Sanda MG
  • A safety-modified SV40 Tag developed for human cancer immunotherapy.
    Drug Des Devel Ther Volume: 2 Page(s): 17 - 24
    02/06/2009 Authors: Tseng-Rogenski SS; Arredouani MS; Escara-Wilke JF; Neeley YC; Imperiale MJ; Sanda MG
  • Standard operating procedures for serum and plasma collection: early detection research network consensus statement standard operating procedure integration working group.
    J Proteome Res Volume: 8 Page(s): 113 - 117
    01/01/2009 Authors: Tuck MK; Chan DW; Chia D; Godwin AK; Grizzle WE; Krueger KE; Rom W; Sanda M; Sorbara L; Stass S
  • Correlation of Gleason Score and Tumor Size with Magnetic Reasonance Image-Detected Prostate Cancer
    Volume: 89 Page(s): 170A - 170A
    01/01/2009 Authors: Genega EM; Bloch NB; Dewolf W; Elliot R; Fu Y; Sanda M; Tomaszewski J; Rofsky N
  • Correlation of Gleason Score and Tumor Size with Magnetic Reasonance Image-Detected Prostate Cancer
    Volume: 22 Page(s): 170A - 170A
    01/01/2009 Authors: Genega EM; Bloch NB; Dewolf W; Elliot R; Fu Y; Sanda M; Tomaszewski J; Rofsky N
  • Seminal Vesicle Invasion at Radical Prostatectomy: Correlation with Magnetic Reasonance Images
    Volume: 22 Page(s): 167A - 167A
    01/01/2009 Authors: Elliott R; Bloch NB; Dewolf W; Fu Y; Sanda M; Tomaszewski J; Wagner A; Rofsky N; Genega EM
  • Seminal Vesicle Invasion at Radical Prostatectomy: Correlation with Magnetic Reasonance Images
    Volume: 89 Page(s): 167A - 167A
    01/01/2009 Authors: Elliott R; Bloch NB; Dewolf W; Fu Y; Sanda M; Tomaszewski J; Wagner A; Rofsky N; Genega EM
  • Phase II trial of paclitaxel, carboplatin and gemcitabine in patients with locally advanced carcinoma of the bladder.
    J Urol Volume: 180 Page(s): 2384 - 2388
    12/01/2008 Authors: Smith DC; Mackler NJ; Dunn RL; Hussain M; Wood D; Lee CT; Sanda M; Vaishampayan U; Petrylak DP; Quinn DI
  • Patterns of care for radical prostatectomy in the United States from 2003 to 2005.
    J Urol Volume: 180 Page(s): 1969 - 1974
    11/01/2008 Authors: Hu JC; Hevelone ND; Ferreira MD; Lipsitz SR; Choueiri TK; Sanda MG; Earle CC
  • Longitudinal analysis of a model to predict quality of life in prostate cancer patients and their spouses.
    Ann Behav Med Volume: 36 Page(s): 117 - 128
    10/01/2008 Authors: Kershaw TS; Mood DW; Newth G; Ronis DL; Sanda MG; Vaishampayan U; Northouse LL
  • Tracking humoral responses using self assembling protein microarrays.
    Proteomics Clin Appl Volume: 2 Page(s): 1518 - 1527
    10/01/2008 Authors: Ramachandran N; Anderson KS; Raphael JV; Hainsworth E; Sibani S; Montor WR; Pacek M; Wong J; Eljanne M; Sanda MG
  • Gene expression profile of mouse prostate tumors reveals dysregulations in major biological processes and identifies potential murine targets for preclinical development of human prostate cancer therapy.
    Prostate Volume: 68 Page(s): 1517 - 1530
    10/01/2008 Authors: Haram KM; Peltier HJ; Lu B; Bhasin M; Otu HH; Choy B; Regan M; Libermann TA; Latham GJ; Sanda MG
  • Fas-mediated T cell deletion potentiates tumor antigen-specific tolerance in a mouse model of prostate cancer.
    Cancer Immunol Immunother Volume: 57 Page(s): 1357 - 1365
    09/01/2008 Authors: Tseng-Rogenski SS; Arredouani MS; Neeley YC; Lu B; Chinnaiyan AM; Sanda MG
  • Development and validation of the convalescence and recovery evaluation (CARE) for measuring quality of life after surgery.
    Qual Life Res Volume: 17 Page(s): 915 - 926
    08/01/2008 Authors: Hollenbeck BK; Dunn RL; Wolf JS; Sanda MG; Wood DP; Gilbert SM; Weizer AZ; Montie JE; Wei JT
  • [-2]proenzyme prostate specific antigen for prostate cancer detection: a national cancer institute early detection research network validation study.
    J Urol Volume: 180 Page(s): 539 - 543
    08/01/2008 Authors: Sokoll LJ; Wang Y; Feng Z; Kagan J; Partin AW; Sanda MG; Thompson IM; Chan DW
  • Quality of life and satisfaction with outcome among prostate-cancer survivors.
    N Engl J Med Volume: 359 Page(s): 201
    07/10/2008 Authors: Vordermark D
  • Characterization of TMPRSS2-ERG fusion high-grade prostatic intraepithelial neoplasia and potential clinical implications.
    Clin Cancer Res Volume: 14 Page(s): 3380 - 3385
    06/01/2008 Authors: Mosquera J-M; Perner S; Genega EM; Sanda M; Hofer MD; Mertz KD; Paris PL; Simko J; Bismar TA; Ayala G
  • Partially circumventing peripheral tolerance for oncogene-specific prostate cancer immunotherapy.
    Prostate Volume: 68 Page(s): 715 - 727
    05/15/2008 Authors: Neeley YC; Arredouani MS; Hollenbeck B; Eng MH; Rubin MA; Sanda MG
  • Utilization of deferred treatment/watchful waiting among prostate cancer survivors in the physicians' health study
    Volume: 179 Page(s): 63 - 64
    04/01/2008 Authors: Shappley WV; Kasperzyk JL; Kenfield SA; Mucci LA; Fleet J; Kurth T; Ma J; Stampfer MJ; Sanda MG
  • Comparison of validated instruments to measure sexual function in a cohort of preoperative prostate cancer patients
    Volume: 179 Page(s): 361 - 361
    04/01/2008 Authors: Levinson AW; Ward NT; Sanda MG; Wei JT; Su L-M; Litwin MS; Pavlovich CP
  • TMPRSS2-ERG fusion prostate cancer prevalence, association with psa density, and histologic features in a multi-center US cohort of men undergoing prostate biopsy
    Volume: 179 Page(s): 705 - 706
    04/01/2008 Authors: Mosquera JM; Mehra R; Regan M; Genega EM; Gaston S; Perner S; Bueti G; Tomlins SA; Shah RB; Wei JT
  • Discrimination of care to patient differences: A useful tool for evaluating quality?
    Volume: 179 Page(s): 27 - 27
    04/01/2008 Authors: Hoilenbeck BK; Dunn RL; Wolf JS; Sanda MG; Montie JE; Gilbert SM; Weizer AZ; Wood DP; Wei JT
  • Is androgen suppression therapy associated with early onset of fatal myocardial infarction?
    Nat Clin Pract Urol Volume: 5 Page(s): 184 - 185
    04/01/2008 Authors: Sanda MG; Kasibhatla M
  • Determinants of long-term retention of prostate cancer patients in active surveillance management programs
    Volume: 179 Page(s): 395 - 395
    04/01/2008 Authors: Shappley WV; Kenfield SA; Kasperzyk JL; Stampfer MJ; Sanda MG; Chan JM
  • Optimizing anti-tumor immunity: Mechanisms and reversion of systemic iNKT defects in murine prostate cancer
    FASEB JOURNAL Volume: 22
    04/01/2008 Authors: Nowak M; Ilyinski P; Arredouani MS; Sanda M; Balk SP; Exley MA
  • Recovery after abdominal and pelvic surgery
    Volume: 179 Page(s): 5 - 6
    04/01/2008 Authors: Hollenbeck BK; Hollingsworth JM; Dunn RL; Wolf JS; Montie JE; Gilbert SM; Weizer AZ; Sanda MG; Wei JT
  • Utilization of pharmacotherapy for erectile dysfunction following surgery for prostate cancer
    Volume: 179 Page(s): 144 - 144
    04/01/2008 Authors: Prasad MM; Hevelone N; Earle CC; Sanda MG; Prasad SM; Hu JC
  • Quality of life and satisfaction with outcome among prostate-cancer survivors.
    N Engl J Med Volume: 358 Page(s): 1250 - 1261
    03/20/2008 Authors: Sanda MG; Dunn RL; Michalski J; Sandler HM; Northouse L; Hembroff L; Lin X; Greenfield TK; Litwin MS; Saigal CS
  • Heterogeneous TMPRSS2-ERG expression in human prostate cancers: Insights from a prospective prostate biopsy series
    CANCER BIOMARKERS Volume: 4 Page(s): 177 - 178
    01/01/2008 Authors: Gaston SM; Kearney MC; Guerra AL; Conroe H; Trejo G; Jung J-N; Bueti G; Hayek J; Mosquera J-M; Perner S
  • Measuring health-related quality of life consequences from primary treatment for early-stage prostate cancer.
    Semin Radiat Oncol Volume: 18 Page(s): 67 - 72
    01/01/2008 Authors: Dandapani SV; Sanda MG
  • Lower limits of detection using magnetic resonance imaging for solid components in cystic renal neoplasms.
    Urology Volume: 71 Page(s): 47 - 51
    01/01/2008 Authors: Adey GS; Pedrosa I; Rofsky NM; Sanda MG; DeWolf WC
  • Prevalence of TMPRSS2-ERG fusion prostate cancer in men undergoing prostate biopsy in the United States
    Volume: 88 Page(s): 172A - 172A
    01/01/2008 Authors: Mosquera JM; Mehra R; Regan M; Genega EM; Gaston S; Perner S; Connor M; Bueti G; Tomlins DA; Shah RB
  • Characterization of TMPRSS2-ERG fusion high-grade prostatic Intraepithelial neoplasia (HGPIN) and potential clinical implications
    Volume: 21 Page(s): 172A - 172A
    01/01/2008 Authors: Mosquera JM; Perner S; Genega EM; Sanda M; Hofer MD; Mertz KD; Paris PL; Simko J; Bismar TA; Ayala G
  • Characterization of TMPRSS2-ERG fusion high-grade prostatic intraepithelial neoplasia (HGPIN) and potential clinical implications
    Volume: 88 Page(s): 172A - 172A
    01/01/2008 Authors: Mosquera JM; Perner S; Genega EM; Sanda M; Hofer MD; Mertz KD; Paris PL; Sinko J; Bismar TA; Ayala G
  • Optimizing anti-tumor immunity: Reversing systemic iNKT cell immunoregulatory defects in murine prostate cancer
    Volume: 127 Page(s): S35 - S36
    01/01/2008 Authors: Nowak M; Arredouani S; Sanda M; Balk S; Exley M
  • Prevalence of TMPRSS2-ERG fusion prostate cancer in men undergoing prostate biopsy in the United States
    Volume: 21 Page(s): 172A - 172A
    01/01/2008 Authors: Mosquera JM; Mehra R; Regan M; Genega EM; Gaslon S; Perner S; Connor M; Bueli G; Tomlins SA; Shah RB
  • [-2]proPSA improves prostate cancer detection: An EDRN validation study
    CANCER BIOMARKERS Volume: 4 Page(s): 135 - 135
    01/01/2008 Authors: Sokoll LJ; Wang Y; Feng Z; Kagan J; Partin AW; Sanda MG; Thompson IM; Chan DW
  • Living with prostate cancer: patients' and spouses' psychosocial status and quality of life.
    J Clin Oncol Volume: 25 Page(s): 4171 - 4177
    09/20/2007 Authors: Northouse LL; Mood DW; Montie JE; Sandler HM; Forman JD; Hussain M; Pienta KJ; Smith DC; Sanda MG; Kershaw T
  • Determinants of satisfaction with outcome in a prospective, multi-center study of prostatectomy, external radiotherapy, or brachytherapy for early stage prostate cancer
    Volume: 177 Page(s): 1 - 1
    04/01/2007 Authors: Dunn RL; Wei JT; Shah N; Sandler HM; Lin X; Michalski J; Hembroff L; Greenfield TK; Litwin MS; Saigal CS
  • Patient-reported outcomes after retropubic, laparoscopic, or robot-assisted prostatectomy: Results from a prospective, multi-center study.
    Volume: 177 Page(s): 184 - 184
    04/01/2007 Authors: Wagner AA; Wei JT; Dunn RL; Hollenbeck BK; Andriole GL; Wood DP; Dahl DM; Hu JC; Hembroff L; Litwin MS
  • [-2]ProPSA for prostate cancer detection: An NCI early detection research network validation study
    Volume: 177 Page(s): 534 - 534
    04/01/2007 Authors: Sokoll LJ; Wang Y; Feng Z; Partin AW; Sanda MG; Thompson IM; Chan DW
  • Prostate size, obesity, and neoadjuvant hormone therapy affect HRQOL in a prospective, multi-center study of prostatectomy, external radiotherapy, or brachytherapy for prostate cancer
    Volume: 177 Page(s): 589 - 589
    04/01/2007 Authors: Sanda MG; Dunn RL; Michalski J; Sandler HM; Hembroff L; Litwin MS; Saigal CS; Mahadevan A; Klein EA; Kibel AS
  • Measuring quality-of-life after surgery: Development and validation of the convalescence and recovery evaluation (CARE)
    Volume: 177 Page(s): 7 - 7
    04/01/2007 Authors: Hollenbeck BK; Wolf JS; Dunn RL; Sanda MG; Wood DP; Montie JE; Wei JT
  • Impact of prostate cancer patient treatment outcome on HRQOL and satisfaction with cancer care among their spouses
    Volume: 177 Page(s): 4 - 4
    04/01/2007 Authors: Wei JT; Northouse L; Dunn RL; Lin X; Michalski J; Sandler HM; Hembroff L; Litwin MS; Saigal CS; Klein EA
  • Measuring patients' expectations regarding health-related quality-of-life outcomes associated with prostate cancer surgery or radiotherapy.
    Urology Volume: 68 Page(s): 1224 - 1229
    12/01/2006 Authors: Symon Z; Daignault S; Symon R; Dunn RL; Sanda MG; Sandler HM
  • Prostate cancer in a transgender woman 41 years after initiation of feminization.
    JAMA Volume: 296 Page(s): 2316 - 2317
    11/15/2006 Authors: Miksad RA; Bubley G; Church P; Sanda M; Rofsky N; Kaplan I; Cooper A
  • Use of medications or devices for erectile dysfunction among long-term prostate cancer treatment survivors: potential influence of sexual motivation and/or indifference.
    Urology Volume: 68 Page(s): 166 - 171
    07/01/2006 Authors: Miller DC; Wei JT; Dunn RL; Montie JE; Pimentel H; Sandler HM; McLaughlin PW; Sanda MG
  • Obesity adversely affects health related quality of life before and after radical retropubic prostatectomy.
    J Urol Volume: 176 Page(s): 257 - 261
    07/01/2006 Authors: Montgomery JS; Gayed BA; Hollenbeck BK; Daignault S; Sanda MG; Montie JE; Wei JT
  • Providing practitioner-specific outcomes is associated with higher patient satisfaction with information about prostate cancer treatment.
    Volume: 24 Page(s): 6106
    06/20/2006 Authors: Gilbert SM; Sanda MG; Dunn RL; Greenfield T; Hembroff L; Klein E; Saigal C; Michalski J; Sandler H; Litwin MS
  • Analysis of hormonal receptor status in tissue from prostate cancer that developed 26 years after bilateral orchiectomy and following 41 years of estrogen therapy.
    J Clin Oncol Volume: 24 Page(s): 14610
    06/20/2006 Authors: Miksad RA; Bubley G; Church P; Cooper A; Rofsky N; Kaplan I; Sanda M
  • Prognostic factors in lymph node-positive prostate cancer.
    Urology Volume: 67 Page(s): 1016 - 1021
    05/01/2006 Authors: Hofer MD; Kuefer R; Huang W; Li H; Bismar TA; Perner S; Hautmann RE; Sanda MG; Gschwend JE; Rubin MA
  • Perioperative quality care indicators of retropubic, laparoscopic, and robotic prostatectomy: Results from a national, multi-center, prospective cohort
    Volume: 175 Page(s): 370 - 370
    04/01/2006 Authors: Hu JC; Wood DP; Andriole GL; Dunn RL; Dahl DM; Hollenbeck BK; Kibel AS; Saigal CS; Litwin MS; Pisters LL
  • Impact of post-prostatectomy urethral strictures on urinary and sexual health related quality of life
    Volume: 175 Page(s): 150 - 151
    04/01/2006 Authors: Montgomery JS; Gayed BA; Hollenbeck BK; Daignault S; Sanda MG; Wei JT
  • Prostate cancer physician performance measured by patient-reported ratings of practitioner manner/skill and by treatment-related adverse events
    Volume: 175 Page(s): 517 - 517
    04/01/2006 Authors: Sanda MG; Dunn RL; Northouse L; Litwin MS; Hembroff L; Sandler HM; Jeff M; Klein EA; Mahadevan A; Kibel AS
  • Early complications following contemporary brachytherapy for prostate cancer in a multi-institutional study at high volume health centers in the US
    Volume: 66 Page(s): S323 - S324
    01/01/2006 Authors: Michalski JM; Ciezki J; Kaplan I; Kuban D; McLaughlin PW; Sandler H; Lee S; Dunn R; Wei J; Sanda M
  • [The Japanese translation and cultural adaptation of Expanded Prostate Cancer Index Composite (EPIC)].
    Nihon Hinyokika Gakkai Zasshi Volume: 96 Page(s): 657 - 669
    11/01/2005 Authors: Takegami M; Suzukamo Y; Sanda MG; Kamoto T; Namiki S; Arai Y; Ogawa O; Fukuhara S; Kakehi Y
  • Autoantibody signatures in prostate cancer.
    N Engl J Med Volume: 353 Page(s): 1224 - 1235
    09/22/2005 Authors: Wang X; Yu J; Sreekumar A; Varambally S; Shen R; Giacherio D; Mehra R; Montie JE; Pienta KJ; Sanda MG
  • Serum antibodies to huntingtin interacting protein-1: a new blood test for prostate cancer.
    Cancer Res Volume: 65 Page(s): 4126 - 4133
    05/15/2005 Authors: Bradley SV; Oravecz-Wilson KI; Bougeard G; Mizukami I; Li L; Munaco AJ; Sreekumar A; Corradetti MN; Chinnaiyan AM; Sanda MG
  • Long-term outcomes among localized prostate cancer survivors: health-related quality-of-life changes after radical prostatectomy, external radiation, and brachytherapy.
    J Clin Oncol Volume: 23 Page(s): 2772 - 2780
    04/20/2005 Authors: Miller DC; Sanda MG; Dunn RL; Montie JE; Pimentel H; Sandler HM; McLaughlin WP; Wei JT
  • Measuring anti-AMACR humoral response as a serum assay to distinguish aggressive from indolent prostate cancer.
    Volume: 173 Page(s): 381 - 382
    04/01/2005 Authors: Bradford TJ; Sanda MG; Laxman B; Sreekumar A; Wei JT; Rubin MA; Ghosh D; Chinnaiyan AM
  • Obesity affects health related quality of life at baseline before and in recovery after radical retropubic prostatectomy
    Volume: 173 Page(s): 184 - 185
    04/01/2005 Authors: Montgomery JS; Hollenbeck BK; Faruzzi SD; Sanda MG; Montie JE; Wei JT
  • Nodular enhancement on magnetic resonance imaging of cystic renal lesions predicts malignancy
    Volume: 173 Page(s): 380 - 381
    04/01/2005 Authors: Adey GS; Sanda MG; Rofsky N; Pedrosa I; DeWolf WC
  • Salvage therapy adversely effects long-term HRQOL among localized prostate cancer treatment survivors
    Volume: 173 Page(s): 224 - 224
    04/01/2005 Authors: Miller DC; Sanda MG; Hollingsworth JM; Dunn RL; Montie JE; Sandler HM; McLaughlin PW; Wei JT
  • Association of race, cancer severity, pre-treatment quality of life, and patient optimism/pessimism with patient selection of primary prostate cancer treatment
    Volume: 173 Page(s): 453 - 453
    04/01/2005 Authors: Sanda MG; Dunn RL; Saigal CS; Klein EA; Pisters LL; Michalski JM; Kibel AS; Mahadevan A; Sandler HM; Kuban DA
  • Neoadjuvant hormone therapy (NHT) leads to immediate impairment of vitality/hormonal and sexual quality of life: Results of a multi-center prospective study
    Volume: 63 Page(s): S76 - S77
    01/01/2005 Authors: Michalski J; Wei J; Dunn R; Mahadevan A; Sandler H; Saigal C; Kuban D; Pisters L; Klein E; Litwin M
  • Patient, surgeon, and treatment characteristics associated with homologous blood transfusion requirement during radical retropubic prostatectomy: multivariate nomogram to assist patient counseling.
    Urology Volume: 64 Page(s): 117 - 122
    07/01/2004 Authors: Dash A; Dunn RL; Resh J; Wei JT; Montie JE; Sanda MG
  • Humoral immune response to alpha-methylacyl-CoA racemase and prostate cancer.
    J Natl Cancer Inst Volume: 96 Page(s): 834 - 843
    06/02/2004 Authors: Sreekumar A; Laxman B; Rhodes DR; Bhagavathula S; Harwood J; Giacherio D; Ghosh D; Sanda MG; Rubin MA; Chinnaiyan AM
  • Sexual health recovery after prostatectomy, external radiation, or brachytherapy for early stage prostate cancer.
    Curr Urol Rep Volume: 5 Page(s): 212 - 219
    06/01/2004 Authors: Hollenbeck BK; Dunn RL; Wei JT; Sandler HM; Sanda MG
  • Neoadjuvant hormonal therapy impairs sexual outcome among younger men who undergo external beam radiotherapy for localized prostate cancer.
    Urology Volume: 63 Page(s): 946 - 950
    05/01/2004 Authors: Hollenbeck BK; Wei JT; Sanda MG; Dunn RL; Sandler HM
  • Racial/ethnic disparities in the treatment of localized/regional prostate cancer.
    J Urol Volume: 171 Page(s): 1504 - 1507
    04/01/2004 Authors: Underwood W; De Monner S; Ubel P; Fagerlin A; Sanda MG; Wei JT
  • The prevalence and outcome of therapy for erectile dysfunction 4 to 8 years following brachytherapy, external radiation and radical prostatectomy for localized prostate cancer
    Volume: 171 Page(s): 239 - 240
    04/01/2004 Authors: Miller DC; Wei JT; Dunn RL; Pimentel H; Sandler HM; McLaughlin WP; Sanda MG
  • Neoadjuvant hormone therapy impairs long-term sexual outcome among younger men that undergo external beam radiotherapy for localized prostate cancer
    Volume: 171 Page(s): 241 - 241
    04/01/2004 Authors: Hollenbeck BK; Wei JT; Sanda MG; Dunn RL; Sandler HM
  • Determinants of patient satisfaction following contemporary therapy for localized prostate cancer: Characterizing the quality of cancer care and the clinical relevance of long-term HRQOL outcomes
    Volume: 171 Page(s): 102 - 102
    04/01/2004 Authors: Miller DC; Wei JT; Pimentel H; Dunn RL; Sandler HM; McLaughlin WP; Sanda MG
  • Elevated alpha-methylacyl-CoA racemase enzymatic activity in prostate cancer.
    Am J Pathol Volume: 164 Page(s): 787 - 793
    03/01/2004 Authors: Kumar-Sinha C; Shah RB; Laxman B; Tomlins SA; Harwood J; Schmitz W; Conzelmann E; Sanda MG; Wei JT; Rubin MA
  • The role of metastasis-associated protein 1 in prostate cancer progression.
    Cancer Res Volume: 64 Page(s): 825 - 829
    02/01/2004 Authors: Hofer MD; Kuefer R; Varambally S; Li H; Ma J; Shapiro GI; Gschwend JE; Hautmann RE; Sanda MG; Giehl K
  • Cause-specific survival is high following radiotherapy or surgery for Gleason score 8-10 prostate cancer
    Volume: 60 Page(s): S232 - S233
    01/01/2004 Authors: Hamstra DA; Dunn R; Wei J; Montie J; Sanda M; Sandler H
  • Postprostatectomy cancer-free survival of African Americans is similar to non-African Americans after adjustment for baseline cancer severity.
    Urol Oncol Volume: 22 Page(s): 20 - 24
    01/01/2004 Authors: Underwood W; Wei J; Rubin MA; Montie JE; Resh J; Sanda MG
  • The role of an 80 kDa fragment of E-cadherin in the metastatic progression of prostate cancer.
    Clin Cancer Res Volume: 9 Page(s): 6447 - 6452
    12/15/2003 Authors: Kuefer R; Hofer MD; Gschwend JE; Pienta KJ; Sanda MG; Chinnaiyan AM; Rubin MA; Day ML
  • Racial/ethnic disparities in the treatment of localized/regional prostate cancer
    GERONTOLOGIST Volume: 43 Page(s): 244 - 244
    10/01/2003 Authors: Underwood W; DeMonner S; Ubel P; Fagerlin A; Sanda M; Wei J
  • Racial variations in pelvic lymph node dissections in older aged men receiving a prostatectomy for prostate cancer
    GERONTOLOGIST Volume: 43 Page(s): 141 - 142
    10/01/2003 Authors: Underwood W; Gonzalez H; Sanda M; Wei J; Wood D
  • Long-term results of three-dimensional conformal adjuvant and salvage radiotherapy after radical prostatectomy.
    Urology Volume: 62 Page(s): 93 - 98
    07/01/2003 Authors: Tsien C; Griffith KA; Sandler HM; McLaughlin P; Sanda MG; Montie J; Reddy S; Hayman JA
  • Multiplex biomarker approach for determining risk of prostate-specific antigen-defined recurrence of prostate cancer.
    J Natl Cancer Inst Volume: 95 Page(s): 661 - 668
    05/07/2003 Authors: Rhodes DR; Sanda MG; Otte AP; Chinnaiyan AM; Rubin MA
  • Molecular markers for predicting biochemical recurrence in men with clinically localized prostate cancer: A multiplex analysis using high-density tissue microarrays
    Volume: 169 Page(s): 179 - 179
    04/01/2003 Authors: Rhodes D; Sanda MG; Chinnaiyan AM; Rubin MA
  • Recommendations for modifying the 2002 AJCC pathology staging system based on accuracy in reflecting prognosis
    Volume: 169 Page(s): 290 - 290
    04/01/2003 Authors: Sanda MG; Dash A; Wei JT; Dunn R; Rubin M
  • Conditionally replicating oncolytic adenovirus Ad-015 allows selective targeting of cytotoxicity to transitional carcinoma cells with mutated p53
    Volume: 169 Page(s): 137 - 137
    04/01/2003 Authors: Shah NL; Escara-Wilke J; Kielb SJ; Roessler BJ; Sanda MG
  • Sociodemographic determinants of knowledge and understanding for men newly diagnosed with prostate cancer
    Volume: 169 Page(s): 14 - 14
    04/01/2003 Authors: Wei JT; Dunn RL; Dunn RL; Sanda MG; McGee H; Tiwari A; Hembroff L; Taub D; Demers R
  • Sexual function recovery after prostatectomy based on quantified pre-prostatectomy sexual function and use of nerve-sparing and seminal vesicle-sparing surgical techniques
    Volume: 169 Page(s): 181 - 181
    04/01/2003 Authors: Sanda MG; Dunn R; Wei JT; Hoag L; Montie JE
  • Determinants of long-term sexual health outcome after radical prostatectomy measured by a validated instrument.
    J Urol Volume: 169 Page(s): 1453 - 1457
    04/01/2003 Authors: Hollenbeck BK; Dunn RL; Wei JT; Montie JE; Sanda MG
  • Use of quality indicators to evaluate the care of patients with localized prostate carcinoma.
    Cancer Volume: 97 Page(s): 1428 - 1435
    03/15/2003 Authors: Miller DC; Litwin MS; Sanda MG; Montie JE; Dunn RL; Resh J; Sandler H; Wei JT
  • Molecular markers for predicting biochemical recurrence in men with clinically localized prostate cancer: A multiplex analysis using high-density tiddue microarrays
    Volume: 83 Page(s): 166A - 166A
    01/01/2003 Authors: Rhodes DR; Sanda MG; Chinnaiyan AM; Rubin MA
  • Development of prostate cancer biomarkers to indentify men suitable for watchful waiting protocols
    Volume: 83 Page(s): 166A - 166A
    01/01/2003 Authors: Rhodes DR; Chinnaiyan AM; Rubin MA
  • Molecular markers for predicting biochemical recurrence in men with clinically localized prostate cancer; A multiplex analysis using high-density tiddue microarrays
    Volume: 16 Page(s): 166A - 166A
    01/01/2003 Authors: Rhodes DR; Sanda MG; Chinnaiyan AM; Rubin MA
  • Development of prostate cancer biomarkers to indentify men suitable for watchful waiting protocols
    Volume: 16 Page(s): 166A - 166A
    01/01/2003 Authors: Rhodes DR; Chinnaiyan AM; Rubin M
  • Contemporary preoperative parameters predict cancer-free survival after radical prostatectomy: a tool to facilitate treatment decisions.
    Urol Oncol Volume: 21 Page(s): 213 - 218
    01/01/2003 Authors: Nelson CP; Dunn RL; Wei JT; Rubin MA; Montie JE; Sanda MG
  • Antigen-specific tumor vaccine efficacy in vivo against prostate cancer with low class I MHC requires competent class II MHC.
    Prostate Volume: 53 Page(s): 183 - 191
    11/01/2002 Authors: Neeley YC; McDonagh KT; Overwijk WW; Restifo NP; Sanda MG
  • The polycomb group protein EZH2 is involved in progression of prostate cancer.
    Nature Volume: 419 Page(s): 624 - 629
    10/10/2002 Authors: Varambally S; Dhanasekaran SM; Zhou M; Barrette TR; Kumar-Sinha C; Sanda MG; Ghosh D; Pienta KJ; Sewalt RGAB; Otte AP
  • Contemporary diagnosis and management of renal angiomyolipoma.
    J Urol Volume: 168 Page(s): 1315 - 1325
    10/01/2002 Authors: Nelson CP; Sanda MG
  • Huntingtin-interacting protein 1 is overexpressed in prostate and colon cancer and is critical for cellular survival.
    J Clin Invest Volume: 110 Page(s): 351 - 360
    08/01/2002 Authors: Rao DS; Hyun TS; Kumar PD; Mizukami IF; Rubin MA; Lucas PC; Sanda MG; Ross TS
  • Prostate cancer involving the bladder neck: recurrence-free survival and implications for AJCC staging modification. American Joint Committee on Cancer.
    Urology Volume: 60 Page(s): 276 - 280
    08/01/2002 Authors: Dash A; Sanda MG; Yu M; Taylor JMG; Fecko A; Rubin MA
  • Quality of life after prostate cancer treatment.
    J Clin Oncol Volume: 20 Page(s): 3038
    07/01/2002 Authors: Lee WR
  • Preoperative parameters for predicting early prostate cancer recurrence after radical prostatectomy.
    Urology Volume: 59 Page(s): 740 - 745
    05/01/2002 Authors: Nelson CP; Rubin MA; Strawderman M; Montie JE; Sanda MG
  • alpha-Methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer.
    JAMA Volume: 287 Page(s): 1662 - 1670
    04/03/2002 Authors: Rubin MA; Zhou M; Dhanasekaran SM; Varambally S; Barrette TR; Sanda MG; Pienta KJ; Ghosh D; Chinnaiyan AM
  • Neoadjuvant hormonal therapy and older age are associated with adverse sexual health-related quality-of-life outcome after prostate brachytherapy.
    Urology Volume: 59 Page(s): 480 - 484
    04/01/2002 Authors: Hollenbeck BK; Dunn RL; Wei JT; McLaughlin PW; Han M; Sanda MG
  • Use of baseline clinical parameters to distinguish indolent prostate cancers suitable for observation from cancers warranting primary intervention
    Volume: 167 Page(s): 336 - 336
    04/01/2002 Authors: Nelson CP; Dunn RL; Wei JT; Rubin MA; Sanda MG
  • Prostate cancer involving the bladder neck: Recurrence-free survival and implications for AJCC staging modifications.
    Volume: 167 Page(s): 222 - 222
    04/01/2002 Authors: Dash A; Sanda MG; Yu MG; Taylor JM; Fecko A; Montie JE; Rubin MA
  • Immunotherapy targeting a specific prostatic antigen prolongs survival in prostate cancer transgenic mice
    Volume: 167 Page(s): 138 - 138
    04/01/2002 Authors: Hollenbeck BK; Neely C; Loveridge J; Shah N; Sanda MG
  • Genetic profiling of hormone refractory prostate cancer implicates EZH2 as a marker to distinguish cancers at risk for lethal progression from indolent prostate cancers
    Volume: 167 Page(s): 301 - 301
    04/01/2002 Authors: Chinnaiyan AM; Varambally S; Dhanasekaran SM; Fecko A; Sanda MG; Pienta KJ; Otte AP; Rubin MA
  • Contemporary pre-operative predictors of clinical recurrence and survival after radical prostatectomy in the PSA era
    Volume: 167 Page(s): 342 - 342
    04/01/2002 Authors: Nelson CP; Dunn RL; Wei JT; Rubin MA; Sanda MG
  • HRQOL determinants of prostate cancer patient satisfaction after prostatectomy, external radiation or brachytherapy at referral and community practices
    Volume: 167 Page(s): 156 - 157
    04/01/2002 Authors: Sanda MG; Dunn R; Wei J; Shah NL; Lutz M; McLaughlin PW; Sandler H; Montie J
  • Pre-operative parameters predict the probability of blood transfusion requirement during radical retropubic prostatectomy: Development of a multivariate nomogram to assist patient counseling
    Volume: 167 Page(s): 356 - 356
    04/01/2002 Authors: Dash A; Dunn RL; Resh J; Montie JE; Sanda MG
  • Seminal vesicle sparing technique is associated with improved sexual HRQOL outcome after radical prostatectomy
    Volume: 167 Page(s): 151 - 151
    04/01/2002 Authors: Sanda MG; Dunn R; Wei J; Resh J; Montie J
  • The effect of functional and mutant p53 on MVAC therapy in human bladder cancer: Implications for molecular targeting of neoadjuvant chemotherapy
    Volume: 167 Page(s): 110 - 110
    04/01/2002 Authors: Shah NL; Kielb SJ; Sanda MG
  • Daily prostate targeting using implanted radiopaque markers.
    Int J Radiat Oncol Biol Phys Volume: 52 Page(s): 699 - 703
    03/01/2002 Authors: Litzenberg D; Dawson LA; Sandler H; Sanda MG; McShan DL; Ten Haken RK; Lam KL; Brock KK; Balter JM
  • Comprehensive comparison of health-related quality of life after contemporary therapies for localized prostate cancer.
    J Clin Oncol Volume: 20 Page(s): 557 - 566
    01/15/2002 Authors: Wei JT; Dunn RL; Sandler HM; McLaughlin PW; Montie JE; Litwin MS; Nyquist L; Sanda MG
  • Genetic profiling of hormone refractory prostate cancer implicates EZH-2 as as a marker to distinguish cancers at risk for lethal progression from indolent prostate cancers
    LABORATORY INVESTIGATION Volume: 82 Page(s): 158A - 158A
    01/01/2002 Authors: Chinnaiyan AM; Varambally S; Dhanasekaran SM; Fecko A; Sanda MG; Otte AP; Pienta KJ; Rubin MA
  • The molecular profile of prostatic hypertrophy using cDNA and tissue microarrays: What genes distinguish it from prostate cancer?
    Volume: 82 Page(s): 159A - 160A
    01/01/2002 Authors: Dash A; Shah R; Dhanasekaran SM; Chinnaiyan AM; Rubin MA
  • The molecular profile of prostatic hypertrophy using cDNA and tissue microarrays: What genes distinguish it from prostate cancer?
    Volume: 15 Page(s): 159A - 160A
    01/01/2002 Authors: Dash A; Shah R; Dhanasekaran SM; Chinnaiyan AM; Rubin MA
  • Prostate cancer involving the bladder neck: Recurrence-free survival and implications for AJCC staging modifications
    MODERN PATHOLOGY Volume: 15 Page(s): 159A - 159A
    01/01/2002 Authors: Dash A; Sanda MG; Yu M; Taylor JMG; Fecko A; Montie JE; Rubin MA
  • Prostate cancer involving the bladder neck: Recurrence-free survival and implications for AJCC staging modifications
    LABORATORY INVESTIGATION Volume: 82 Page(s): 159A - 159A
    01/01/2002 Authors: Dash A; Sanda MG; Yu M; Taylor JMG; Fecko A; Montie JE; Rubin MA
  • Assessment of early continence recovery after radical prostatectomy: patient reported symptoms and impairment.
    J Urol Volume: 166 Page(s): 958 - 961
    09/01/2001 Authors: Kielb S; Dunn RL; Rashid MG; Murray S; Sanda MG; Montie JE; Wei JT
  • Functional p53 mutation as a molecular determinant of paclitaxel and gemcitabine susceptibility in human bladder cancer.
    J Urol Volume: 166 Page(s): 482 - 487
    08/01/2001 Authors: Kielb SJ; Shah NL; Rubin MA; Sanda MG
  • Bladder neck-sparing radical prostatectomy and positive margins - Reply
    UROLOGY Volume: 58 Page(s): 134 - 134
    07/01/2001 Authors: Sanda M
  • Mxi1, a Myc antagonist, suppresses proliferation of DU145 human prostate cells.
    Prostate Volume: 47 Page(s): 194 - 204
    05/15/2001 Authors: Taj MM; Tawil RJ; Engstrom LD; Zeng Z; Hwang C; Sanda MG; Wechsler DS
  • Prospects for an SV40 vaccine.
    Semin Cancer Biol Volume: 11 Page(s): 81 - 85
    02/01/2001 Authors: Imperiale MJ; Pass HI; Sanda MG
  • Posttranslational truncation and inactivation of human E-cadherin distinguishes prostate cancer from matched normal prostate.
    Cancer Res Volume: 61 Page(s): 489 - 492
    01/15/2001 Authors: Rashid MG; Sanda MG; Vallorosi CJ; Rios-Doria J; Rubin MA; Day ML
  • Surgical margin status adds predictive value to prostate cancer staging: Single institution study of 1050 radical prostatectomy cases.
    MODERN PATHOLOGY Volume: 14 Page(s): 122A - 122A
    01/01/2001 Authors: Sanda M; Manley S; Rubin MA
  • Radiation Therapy Oncology Group. Research Plan 2002-2006. Genitourinary Cancer Committee.
    Int J Radiat Oncol Biol Phys Volume: 51 Page(s): 28 - 38
    01/01/2001 Authors: Sandler H; Shipley WU; Gomella L; Pienta K; Bard RH; Bruner D; Clark R; DeSilvio M; Gaspar L; Gillin M
  • Predictors of Gleason pattern 4/5 prostate cancer on prostatectomy specimens: can high grade tumor be predicted preoperatively?
    J Urol Volume: 165 Page(s): 114 - 118
    01/01/2001 Authors: Rubin MA; Mucci NR; Manley S; Sanda M; Cushenberry E; Strawderman M; Montie JE; Bassily NH
  • Surgical margin status adds predictive value to prostate cancer staging: Single institution study of 1050 radical prostatectomy cases.
    LABORATORY INVESTIGATION Volume: 81 Page(s): 122A - 122A
    01/01/2001 Authors: Sanda M; Manley S; Rubin MA
  • Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer.
    Urology Volume: 56 Page(s): 899 - 905
    12/20/2000 Authors: Wei JT; Dunn RL; Litwin MS; Sandler HM; Sanda MG
  • Benign prostatic glands at surgical margins of radical prostatectomy specimens: frequency and associated risk factors.
    Urology Volume: 56 Page(s): 721 - 725
    11/01/2000 Authors: Shah R; Bassily N; Wei J; Mucci NR; Montie JE; Sanda MG; Rubin MA
  • Prospective assessment of patient reported urinary continence after radical prostatectomy.
    J Urol Volume: 164 Page(s): 744 - 748
    09/01/2000 Authors: Wei JT; Dunn RL; Marcovich R; Montie JE; Sanda MG
  • A comparison of ventilatory prostate movement in four treatment positions.
    Int J Radiat Oncol Biol Phys Volume: 48 Page(s): 319 - 323
    09/01/2000 Authors: Dawson LA; Litzenberg DW; Brock KK; Sanda M; Sullivan M; Sandler HM; Balter JM
  • Bladder neck-sparing modification of radical prostatectomy adversely affects surgical margins in pathologic T3a prostate cancer.
    Urology Volume: 55 Page(s): 904 - 908
    06/01/2000 Authors: Marcovich R; Wojno KJ; Wei JT; Rubin MA; Montie JE; Sanda MG
  • Antitumor efficacy of tumor-antigen-encoding recombinant poxvirus immunization in Dunning rat prostate cancer: implications for clinical genetic vaccine development.
    World J Urol Volume: 18 Page(s): 136 - 142
    04/01/2000 Authors: Charles LG; Xie YC; Restifo NP; Roessler B; Sanda MG
  • Relationship and significance of greatest percentage of tumor and perineural invasion on needle biopsy in prostatic adenocarcinoma.
    Am J Surg Pathol Volume: 24 Page(s): 183 - 189
    02/01/2000 Authors: Rubin MA; Bassily N; Sanda M; Montie J; Strawderman MS; Wojno K
  • Cancer cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer as vaccines for the treatment of genitourinary malignancies.
    Cancer Chemother Pharmacol Volume: 46 Suppl Page(s): S67 - S72
    01/01/2000 Authors: Nelson WG; Simons JW; Mikhak B; Chang JF; DeMarzo AM; Carducci MA; Kim M; Weber CE; Baccala AA; Goeman MA
  • Collagen injection for the treatment of incontinence after cystectomy and orthotopic neobladder reconstruction in women.
    J Urol Volume: 163 Page(s): 212 - 214
    01/01/2000 Authors: Tchetgen MB; Sanda MG; Montie JE; Faerber GJ
  • Early castration reduces prostatic carcinogenesis in transgenic mice.
    Urology Volume: 54 Page(s): 1112 - 1119
    12/01/1999 Authors: Eng MH; Charles LG; Ross BD; Chrisp CE; Pienta KJ; Greenberg NM; Hsu CX; Sanda MG
  • Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer.
    Cancer Res Volume: 59 Page(s): 5160 - 5168
    10/15/1999 Authors: Simons JW; Mikhak B; Chang JF; DeMarzo AM; Carducci MA; Lim M; Weber CE; Baccala AA; Goemann MA; Clift SM
  • Prospects and limitations of recombinant poxviruses for prostate cancer immunotherapy.
    Curr Opin Mol Ther Volume: 1 Page(s): 471 - 479
    08/01/1999 Authors: Hwang C; Sanda MG
  • Recombinant vaccinia-PSA (PROSTVAC) can induce a prostate-specific immune response in androgen-modulated human prostate cancer.
    Urology Volume: 53 Page(s): 260 - 266
    02/01/1999 Authors: Sanda MG; Smith DC; Charles LG; Hwang C; Pienta KJ; Schlom J; Milenic D; Panicali D; Montie JE
  • Induction of tumor antigen-specific immunity in vivo by a novel vaccinia vector encoding safety-modified simian virus 40 T antigen.
    J Natl Cancer Inst Volume: 91 Page(s): 169 - 175
    01/20/1999 Authors: Xie YC; Hwang C; Overwijk W; Zeng Z; Eng MH; Mul JJ; Imperiale MJ; Restifo NP; Sanda MG
  • Longitudinal cohort analysis of lethal prostate cancer progression in transgenic mice.
    J Urol Volume: 160 Page(s): 1500 - 1505
    10/01/1998 Authors: Hsu CX; Ross BD; Chrisp CE; Derrow SZ; Charles LG; Pienta KJ; Greenberg NM; Zeng Z; Sanda MG
  • Comparison of radical prostatectomy and iodine 125 interstitial radiotherapy for the treatment of clinically localized prostate cancer: A 7-year biochemical (PSA) progression analysis - Comment
    UROLOGY Volume: 51 Page(s): 890 - 890
    06/01/1998 Authors: Sanda MG
  • Prospective longitudinal analysis of patient reported outcomes after radical prostatectomy.
    JOURNAL OF UROLOGY Volume: 159 Page(s): 62 - 62
    05/01/1998 Authors: Sanda MG; Wei JT; King K; Oesterling JE; Montie JE
  • Validation of the pathologic TNM staging system for prostate cancer
    JOURNAL OF UROLOGY Volume: 159 Page(s): 299 - 299
    05/01/1998 Authors: Wojno KJ; Putzi MJ; Oesterling JE; Montie JE; Sanda MG
  • 3-dimensional conformal radiation therapy following radical prostatectomy for prostate cancer
    JOURNAL OF UROLOGY Volume: 159 Page(s): 64 - 64
    05/01/1998 Authors: Hayman JA; Wang SB; McLaughlin PW; Sullivan MA; Sanda MG; Montie JE; Reddy SC; Watson GA; Johnson NF; Sandler HM
  • Clinical and biological characteristics of familial benign prostatic hyperplasia.
    J Urol Volume: 157 Page(s): 876 - 879
    03/01/1997 Authors: Sanda MG; Doehring CB; Binkowitz B; Beaty TH; Partin AW; Hale E; Stoner E; Walsh PC
  • Biological principles and clinical development of prostate cancer gene therapy.
    Semin Urol Oncol Volume: 15 Page(s): 43 - 55
    02/01/1997 Authors: Sanda MG
  • A Bcl-x(s) adenovirus vector to selectively kill cancer cells derived from epithelial tissues.
    Volume: 88 Page(s): 793 - 793
    11/15/1996 Authors: Clarke MF; Nunez G; Sanda M; Wicha M
  • Histopathologic characterization of hereditary benign prostatic hyperplasia.
    Urology Volume: 48 Page(s): 650 - 653
    10/01/1996 Authors: Doehring CB; Sanda MG; Partin AW; Sauvageot J; Juo H; Beaty TH; Epstein JI; Hill G; Walsh PC
  • Evolution of outcomes with the ileal hydraulic valve continent diversion: reevaluation of the Benchekroun catheterizable stoma.
    World J Urol Volume: 14 Page(s): 108 - 111
    01/01/1996 Authors: Sanda MG; Jeffs RD; Gearhart JP
  • LOSS OF HLA CLASS-I EXPRESSION IN PROSTATE-CANCER - IMPLICATIONS FOR IMMUNOTHERAPY - EDITORIAL COMMENT
    UROLOGY Volume: 46 Page(s): 686 - 687
    11/01/1995 Authors: SANDA M
  • Selection of men at high risk for disease recurrence for experimental adjuvant therapy following radical prostatectomy.
    Urology Volume: 45 Page(s): 831 - 838
    05/01/1995 Authors: Partin AW; Piantadosi S; Sanda MG; Epstein JI; Marshall FF; Mohler JL; Brendler CB; Walsh PC; Simons JW
  • GENETIC SUSCEPTIBILITY OF BENIGN PROSTATIC HYPERPLASIA - REPLY
    JOURNAL OF UROLOGY Volume: 153 Page(s): 751 - 752
    03/01/1995 Authors: SANDA MG; BEATTY TH; STUTZMAN RE; CHILDS B; WALSH PC
  • Molecular characterization of defective antigen processing in human prostate cancer.
    J Natl Cancer Inst Volume: 87 Page(s): 280 - 285
    02/15/1995 Authors: Sanda MG; Restifo NP; Walsh JC; Kawakami Y; Nelson WG; Pardoll DM; Simons JW
  • Retroperitoneoscopy: effects of insufflation media on surrounding tissue during balloon rupture.
    J Endourol Volume: 9 Page(s): 67 - 71
    02/01/1995 Authors: Moore RG; Demaree RD; Sanda MG; Kavoussi LR
  • Concordance rates for benign prostatic disease among twins suggest hereditary influence.
    Urology Volume: 44 Page(s): 646 - 650
    11/01/1994 Authors: Partin AW; Page WF; Lee BR; Sanda MG; Miller RN; Walsh PC
  • Gene therapy for urologic cancer.
    Urology Volume: 44 Page(s): 617 - 624
    10/01/1994 Authors: Sanda MG; Simons JW
  • Genetic susceptibility of benign prostatic hyperplasia.
    J Urol Volume: 152 Page(s): 115 - 119
    07/01/1994 Authors: Sanda MG; Beaty TH; Stutzman RE; Childs B; Walsh PC
  • Demonstration of a rational strategy for human prostate cancer gene therapy.
    J Urol Volume: 151 Page(s): 622 - 628
    03/01/1994 Authors: Sanda MG; Ayyagari SR; Jaffee EM; Epstein JI; Clift SL; Cohen LK; Dranoff G; Pardoll DM; Mulligan RC; Simons JW
  • Phase I trial of recombinant human macrophage colony-stimulating factor administered by continuous intravenous infusion in patients with metastatic cancer.
    J Natl Cancer Inst Volume: 86 Page(s): 39 - 45
    01/05/1994 Authors: Cole DJ; Sanda MG; Yang JC; Schwartzentruber DJ; Weber J; Ettinghausen SE; Pockaj BA; Kim HI; Levin RD; Pogrebniak HW
  • GENE-THERAPY FOR HUMAN PROSTATE-CANCER - EFFICACY IN ANIMAL-MODELS AND FEASIBILITY FOR HUMAN TRIALS
    JOURNAL OF CELLULAR BIOCHEMISTRY Page(s): 251 - 251
    01/01/1994 Authors: CARDUCCI M; SANDA M; AYYAGARI S; KIM W; COHEN L; MULLIGAN R; PARDOLL D; SIMONS J
  • THE RETROVIRAL VECTOR MFG ALLOWS HIGH-EFFICIENCY TRANSDUCTION OF HUMAN PROSTATE-CANCER CELLS - IMPLICATIONS FOR GENE-THERAPY OF PROSTATE-CANCER
    JOURNAL OF CELLULAR BIOCHEMISTRY Page(s): 120 - 120
    03/13/1993 Authors: SANDA MG; AYYAGARI S; JAFFEE L; PARDOLL DM; MULLIGAN RC; SIMONS JW
  • Intravenous administration of recombinant human macrophage colony-stimulating factor to patients with metastatic cancer: a phase I study.
    J Clin Oncol Volume: 10 Page(s): 1643 - 1649
    10/01/1992 Authors: Sanda MG; Yang JC; Topalian SL; Groves ES; Childs A; Belfort R; de Smet MD; Schwartzentruber DJ; White DE; Lotze MT
  • In vivo administration of recombinant macrophage colony-stimulating factor induces macrophage-mediated antibody-dependent cytotoxicity of tumor cells.
    J Immunother (1991) Volume: 12 Page(s): 132 - 137
    08/01/1992 Authors: Sanda MG; Bolton E; Mul JJ; Rosenberg SA
  • Identification of unique murine tumor associated antigens by tumor infiltrating lymphocytes using tumor specific secretion of interferon-gamma and tumor necrosis factor.
    J Immunol Methods Volume: 140 Page(s): 269 - 279
    07/05/1991 Authors: Barth RJ; Mul JJ; Asher AL; Sanda MG; Rosenberg SA
  • INVIVO ADMINISTRATION OF M-CSF INDUCES PERITONEAL-EXUDATE CELLS THAT MEDIATE ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY
    Volume: 5 Page(s): A1333 - A1333
    03/15/1991 Authors: SANDA MG; BOLTON E; MULE JJ; ROSENBERG SA
  • Serum dipeptidyl peptidase IV in cardiac transplant recipients.
    Transplant Proc Volume: 21 Page(s): 2525 - 2526
    02/01/1989 Authors: Sanda MG; Pierson R; Smith C; Reemtsma K; Rose E
Read more publications Fewer publications
Directory
  • Faculty Profiles
Emory University Homepage

Contact & Location

Emory University School of Medicine
100 Woodruff Circle
Atlanta, GA  30322 USA
  • Contact Us
  • Maps & Directions
  • Careers

Information For

  • Alumni
  • Faculty & Staff
  • Patients
  • Residents & Fellows
  • Students
Support the School of Medicine School of Medicine Intranet
facebook facebook twitter twitter linkedin linkedin instagram instagram youtube youtube
© 2025 Emory University
  • Privacy Policy
  • Emergency Information
  • EEO Employer-Disability/Veteran Statements